



2022 North America  
Conference on  
Lung Cancer

# PROGRAM BOOK

CHICAGO, ILLINOIS

**September 23 – 25, 2022**



#NACLC22







# IASLC 2022 Asia Conference on Lung Cancer

OCTOBER 27-29, 2022 | NARA, JAPAN

## Register Now

### CONNECT WITH US



# #ACLC22

<https://aclc2022.iaslc.org/>

## TABLE OF CONTENTS

WELCOME MESSAGE .....	5
IASLC & CONFERENCE COMMITTEE .....	7
International Association for the Study of Lung Cancer.....	8
Conference Committee.....	8
GENERAL CONFERENCE INFORMATION .....	11
Health & Safety Measures at NACLC 2022 .....	11
Floor Plan.....	11
Conference Registration.....	12
Poster Viewing & Networking Breaks.....	12
Breakfast.....	12
Onsite Service & General Information .....	12
Press & Media .....	14
CONTINUING MEDICAL EDUCATION (CME) INFORMATION .....	17
INFORMATION FOR SPEAKERS & ABSTRACT PRESENTERS .....	21
NACLC 2022 EDUCATION AWARDS.....	23
SCIENTIFIC PROGRAM .....	27
Program at a Glance.....	27
Friday, September 23, 2022.....	28
Saturday, September 24, 2022 .....	29
Sunday, September 25, 2022 .....	32
POSTER SESSIONS .....	35
POSTER DISCUSSIONS.....	41
ABSTRACT AUTHOR INDEX .....	43
EXHIBIT & INDUSTRY SUPPORTER INFORMATION .....	49
Exhibition Hours .....	49
Exhibition Events & Highlights .....	49
Industry Supporter & Exhibitor List .....	50
Exhibit Floor Plan .....	51
Exhibitor Descriptions .....	52
INDUSTRY SYMPOSIA .....	57



### CONFERENCE SECRETARIAT

International Conference  
Services Ltd. (ICS)

Suite 710, 1201 West Pender Street,  
Vancouver, BC, Canada, V6E 2V2  
Phone: +1 604 681 2153  
[www.icsevents.com](http://www.icsevents.com)

### GLOBAL OFFICES

Vancouver, Toronto, Denver,  
London, Barcelona, Vienna,  
Tokyo, Singapore



# WELCOME MESSAGE



## Welcome Message

Dear Colleagues, Friends, Sponsors and Exhibitors,

On behalf of the International Association for the Study of Lung Cancer (IASLC) we are pleased to welcome you to the IASLC 2022 North America Conference on Lung Cancer (#NACLC22) at the Chicago Marriott Downtown Magnificent Mile. The North America Conference on Lung Cancer is a dynamic meeting with a long tradition and close to 500 participants will join us this year to discuss important topics related to thoracic malignancies. The Conference is a fabulous opportunity to network across disciplines with other people with careers focused on thoracic malignancies and learn about the latest developments in prevention, detection and care with novel data presentations. We encourage you to actively participate in the discussions, engage with our industry supporters and join us for the poster viewing reception on Saturday evening. We are also hosting a special Networking Lunch Women’s Forum on Sunday, September 25 which all delegates are welcome to attend.

We also would like to extend our gratitude and thanks to all industry supporters and exhibitors for their support to NACLC and the IASLC. Without them this Conference would not be possible.

Thank you for joining us in Chicago.

We look forward to hosting all of you over the next couple of days.

Best Regards,



**Jessica Donington, MD**  
NACLC 2022 Co-Chair



**Marina Garassino, MD**  
NACLC 2022 Co-Chair



**Jyoti Patel, MD**  
NACLC 2022 Co-Chair



**Everett Vokes, MD**  
NACLC 2022 Steering Committee



**Heather Wakelee, MD**  
NACLC 2022 Steering Committee



# IASLC & CONFERENCE COMMITTEE



## IASLC & Conference Committee

### International Association for the Study of Lung Cancer

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 6,000 lung cancer specialists from over 100 countries.

IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. The IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

#### The IASLC mission is:

- To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies.
- To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public.
- To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.



999 17th Street, Suite 200  
Denver, Colorado 80202-2725  
Phone: 1-855-GO-IASLC (1-855-464-2752)

## IASLC Staff

<b>Karen Kelly</b> Chief Executive Officer	<b>Kelsey Hecker</b> Conference Coordinator	<b>Kelsey Wood</b> Associate Director, Member Experience
<b>John Skadow</b> Chief Financial Officer	<b>O’Ryan Jackson</b> Administrative Assistant	<b>Kelly Wright</b> Member Experience Coordinator
<b>Matt Yeingst</b> Chief Development Officer	<b>Vun Sin Lim</b> Editorial Consultant JTO Clinical and Research Reports	<b>Murry Wynes</b> Senior Advisor, Scientific Affairs
<b>Tessa Baxter</b> ILC Foundation Coordinator / Project Manager	<b>Sara Lindsey Patton</b> Patient Advocacy Specialist	<b>Kexin Yu</b> Accountant
<b>Becky Bunn</b> Senior Advisor, Scientific Relations	<b>Katie Maher</b> Member Experience Specialist	<b>Flavia Zarcula</b> Corporate Relations Manager
<b>Mya Burns</b> Associate Director, Conferences	<b>Sunhee Malinowski</b> Account Manager	
<b>Casey Connolly</b> Scientific Affairs Specialist	<b>Jan Mazotti</b> Associate Director, Marketing and Communications	
<b>Bailey Creamer</b> Editorial Assistant	<b>Karen Muth</b> Executive Assistant and Board Liaison	
<b>Kathy Doherty</b> Director, Human Resources	<b>Rodrigo Sagastegui</b> Marketing Specialist	
<b>Ken Harrell</b> Database Administrator	<b>Mary Todd</b> Managing Editor, JTO & JTO CRR	
<b>Kelly Heemsbergen</b> Conference Manager		



## IASLC Board of Directors 2021 – 2023

Officers	President <b>Heather Wakelee, United States</b>	Secretary <b>Andrea Bezjak, Canada</b>
	Past-President <b>Tetsuya Mitsudomi, Japan</b>	Treasurer <b>Erik Thunnissen, Netherlands</b>
	President-Elect <b>Paul Van Schil, Belgium</b>	Chief Executive Officer <b>Karen Kelly, United States</b>
Board of Directors	<b>Joachim Aerts</b> , Netherlands	<b>Morten Quist</b> , Denmark
	<b>Carlos Gil Moreira Ferreira</b> , Brazil	<b>Lecia Sequist</b> , United States
	<b>Jhanelle Gray</b> , United States	<b>Ming-Sound Tsao</b> , Canada
	<b>Roy Herbst</b> , United States	<b>Paula Ugalde</b> , United States
	<b>Young Tae Kim</b> , South Korea	<b>Caicun Zhou</b> , China

## Conference Committee

Meeting Co-Chairs	Jessica Donington, United States	Steering Committee	Everett Vokes, United States
	Marina Garrasino, United States		Heather Wakelee, United States
	Jyoti Patel, United States		

### Program Committee

#### Medical Oncology

Frank Weinberg, United States  
Greg Durm, United States  
Angel Qin, United States  
Mary Jo Fidler, United States  
Salama Waqar, United States  
Christine Bestvina, United States

#### Radiation Oncology

Aditya Juloori, United States  
Pamela Sampson, United States  
Gaurav Marwaha, United States

#### Pathology

Aliya Husein, United States  
Mary Beth Beasley, United States

#### Surgery

David Odell, United States  
Duy Khanh Ceppa, United States  
Erin Gillaspie, United States

#### Pulmonology

Tim Murgu, United States  
Scott Ferguson, United States

#### Translational Science

Mohamed Abazeed, United States  
Sean Pitroda, United States  
Jessica Lin, United States  
Tina Cascone, United States

#### Mesothelioma, Thymoma

Hedy Lee Kindler, United States  
Anne Tsao, United States  
Patrick Loehrer, United States

#### Tobacco Control, Environmental Exposure, Risk Reduction and Screening

Jim Mulshine, United States  
Loretta Erhunmwunsee, United States  
Betty Tran, United States

#### Community Practice

Jane Liu, United States  
Avanthi Ragam, United States

#### Nursing & AHP

Livia Szeto, United States  
Michelle Turner, United States

#### Patient Advocacy

Upal Basu Roy, United States  
Jill Feldman, United States  
Ivy Elkins, United States

**Immunohistochemistry is an extremely valuable and powerful technique for pathologic diagnosis.**


Published by the IASLC and its Pathology Committee, the IHC Atlas takes a comprehensive look at diagnostic IHC and its role in thoracic pathology.

The IHC Atlas is a useful reference for anyone interested in thoracic tumor diagnostics, from basic researchers to practicing oncologists. All pathologists should have access to these best practices. The Atlas is available in multiple languages.

**Scan the QR code to order your copy today!**



**Coming Soon!**  
**IASLC Atlas on  
Molecular Biomarker  
Testing for Targeted  
Therapy**  
Available at #TTLC23






# GENERAL INFORMATION



## General Conference Information

The IASLC 2022 North America Conference on Lung Cancer (NACLC 2022) is being held at the Chicago Marriott Downtown Magnificent Mile. Session rooms, Exhibit and Poster Hall, and Registration are located on the 5th Floor, except for the Opening Keynote Session and CURE® Lung Cancer Heroes® Cocktail Reception, on September 23, 2022 which will be held at Marriott Ballroom and Halstead Foyer on the 4th Floor.



**Chicago Marriott Downtown Magnificent Mile**  
540 North Michigan Avenue, Chicago, IL 60611, United States

## Health & Safety Measures at NACLC 2022

NACLC 2022 will be hosted as an in-person meeting in Chicago, Illinois, USA at the Chicago Marriott Downtown Magnificent Mile. The health and safety of all our stakeholders are of the utmost importance. Although we are excited to welcome you to Chicago, all necessary precautions will be taken to ensure a safe environment throughout the Conference.

The following measures are in place and enforced on-site to achieve this commitment (applicable to all staff, delegates, exhibitors, industry supporters, and guests):

### VACCINATION POLICY

NACLC 2022 recommends that all in-person attendees are fully vaccinated against COVID-19 by the time of the Conference. Fully vaccinated refers to completing the approved first 2 vaccines, as per the guidelines of their country of residence.

All participants, including attendees, speakers, staff, and suppliers will be asked to present proof of full vaccination and photo ID with a matching name prior to entry into the Conference Venue.

### Accepted Forms of Proof:

*(Note: Proof of vaccination must match the Attendee's name)*

- Copy of an official certificate from your Country/State/Province
- Photo of the official certificate
- Digital PDF or document of the official certificate on a mobile device
- Accepted Vaccines: as per approved guidelines from the country of residence

In the absence of a proof of vaccination, the IASLC will accept a valid negative test result (from within 24 hours to 48 hours), with no symptoms.

If you cannot or choose not to comply with the IASLC health and safety protocols, or if you are unable to come to Chicago, please join us virtually for #NACLC22.

### MASK REQUIREMENT

Masks will be encouraged to be worn at NACLC 2022.

### By registering to attend, you agree that:

You will not attend if you have any COVID-19 symptoms. If during your attendance you develop any COVID-19 symptoms, you will immediately:


- Self-isolate;
- Comply with all local/national government restrictions; and
- Inform the NACLC 2022 Conference Secretariat by email ([nalc2022-Registration@icsevents.com](mailto:nalc2022-Registration@icsevents.com)).

IASLC and their suppliers will in their best effort, provide a safe environment to meet. It is expected that all participants will follow the measures to help reduce the risk.

*Please note: There is no on-site testing facility available at NACLC 2022.*



## Floor Plan



## Poster Viewing & Networking Breaks

(Snacks and refreshments provided)

Chicago Ballroom FGH | 5th Floor

Saturday, September 24	09:30 - 10:00 14:30 - 15:00
Saturday, September 24 (Poster Viewing Reception)	17:40 - 18:55
Sunday, September 25	09:15 - 09:45

## Networking Breaks Supporter



## Saturday Networking Breakfast Supporter



## Sunday Networking Breakfast Supporter



## Conference Registration

Registration Counter | 4th Floor  
Friday, September 23

Registration Counter | 5th Floor  
Saturday, September 24 and  
Sunday, September 25

## Registration Desk Hours

Friday, September 23	4th Floor	15:30 - 19:30
Saturday, September 24	5th Floor	06:00 - 19:30
Sunday, September 25	5th Floor	06:00 - 13:00

## Name Badges

Attendees are requested to wear their name badges at all times in order to participate in the Scientific Sessions and Exhibition.



## Networking Breakfast & Lunch

A light breakfast/lunch will be provided.

Chicago Ballroom Foyer | 5th Floor

Saturday, September 24	07:00 - 08:00 11:30 - 12:30
Sunday, September 25	07:00 - 08:00

## Poster Viewing Reception Supporter



## Saturday Networking Luncheon Supporter



## Women in Lung Cancer Networking Lunch Supporter



## ABSTRACTS

Accepted abstracts will be presented in Oral, Poster Discussion and Poster Sessions. All presented abstracts will be published in a supplement of the *Journal of Thoracic Oncology* which will be posted online on the JTO website in November 2022.

## ACCREDITATION

Please refer to page 17 in this book for further information.

## ATTIRE

Business casual is appropriate for all sessions. Room temperature can vary in session rooms. We encourage attendees to dress in layers for their personal comfort.

## BADGES AND ACCESS CONTROL

You will be required to wear your badge at all times within the venue.

## BREAKFAST

A light breakfast will be provided in the Chicago Ballroom Foyer on the 5th Floor from 07:00 - 08:00 on Saturday, September 24 and Sunday, September 25.

## Prayer / Mothers Room

IASLC is offering delegates the use of a private nursing room and the use of a multifaith prayer room located at the Kansas City Room on the fifth floor.

Kansas City Room | 5th Floor

## CELL PHONES

As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.

## CERTIFICATE OF ATTENDANCE

Delegates can download their 'Certificate of Attendance' after completing the online Conference evaluation form, which will be sent to all registered delegates at the conclusion of the Conference.

## IASLC NACLC 2022 VIRTUAL MEETING PLATFORM

All sessions will be audio recorded and made available on the Virtual Platform within 24 hours. Sessions that are live-streamed can be watched via the Virtual Platform. The Virtual Platform also includes presentation slides, abstracts and posters.

Log-in details including passwords are sent to your registered email along with the Final Confirmation email. If you need assistance, please contact:

[nalc2022-registration@icsevents.com](mailto:nalc2022-registration@icsevents.com).

Access the NACLC 2022 Virtual Platform at

<https://nalc22-iaslc.junolive.co/>.

## Prayer/ Mothers Room Timings

Friday, September 23	17:30 - 19:30
Saturday, September 24	06:00 - 20:30
Sunday, September 25	06:00 - 13:30

## LOST AND FOUND / MESSAGES

Lost and found items should be returned / claimed at the Registration Desk.

## NETWORKING BREAKS

On the Conference days, refreshments will be available outside the Exhibit and Poster Hall during the scheduled morning and afternoon Networking Breaks.

## PARKING

The Hotel has off-site Parking located at the corner of Rush & Ohio Street. Please contact Chicago Marriott Downtown Magnificent Mile for further details.

## POSTERS ONLINE

All abstracts accepted for poster presentations will be presented as traditional printed posters to be displayed on poster boards in the Exhibit and Poster Hall (Chicago Ballroom FGH). In addition to the printed poster, each presenter is required to submit an electronic version of their poster to be made available in the virtual meeting platform, which is available to all registered delegates.

## SMOKING

The Chicago Marriott Downtown Magnificent Mile is a smoke-free environment. All public areas, rental space, corridors, loading docks, Exhibit and Poster Halls, and parking lots are designated non-smoking. The Chicago Marriott Downtown Magnificent Mile is required to enforce the no-smoking rules.



**FREE Wi-Fi**

Wi-Fi will be provided in the meeting and exhibit space.

Network: **NACLC22**

Password: **IASLC2022**

### IASLC Social Media Accounts

 facebook.com/IASLC

 IASLC

 @IASLC

 iaslungcancer

 IASLC

### DISCLAIMER

The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.

### PRESS & MEDIA

Pre-registered Press and Media representatives are required to check-in at the registration desk. Non-registered Press and Media representatives should also proceed to the registration desk and need to provide their press/media credentials to receive their Conference name badge.

### USE OF NACLC 2022 SCIENTIFIC PROGRAM CONTENT

Please be aware that the information and materials displayed and/or presented at all sessions of this meeting are the property of the International Association for the Study of Lung Cancer (IASLC) 2022 North America Conference on Lung Cancer and cannot be photographed, copied, photocopied, transformed to electronic format, reproduced or distributed without the written permission of the IASLC. Use of the NACLC/IASLC name and/or logo in any fashion by any commercial entity for any purpose is expressly prohibited without the written permission of the IASLC.



# Journal of Thoracic Oncology

*Official Journal of the International Association for the Study of Lung Center*

Editor-in-Chief:

**Alex A. Adjei, MD, PhD, FACP**

*Chairman, Taussig Cancer Institute – Cleveland Clinic, Cleveland, OH USA*

The **Journal of Thoracic Oncology (JTO)**, the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of thoracic malignancies. **JTO** emphasizes a multidisciplinary approach, and includes original research (clinical trials, and translational or basic research), reviews, and opinion pieces. The audience consists of epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonary specialists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology.



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER

2021 Journal  
Impact Factor\*

**20.121**

\*Journal Citation Reports®  
(Clarivate Analytics, 2022)



A subscription to **JTO** is a benefit of membership in the IASLC. To join, visit [www.IASLC.org](http://www.IASLC.org).

visit  
**jto.org**





# CONTINUING MEDICAL EDUCATION (CME) INFORMATION



#NACLC22

#NACLC22 | [nalc2022.iaslc.org](https://nalc2022.iaslc.org)

## Continuing Medical Education (CME) Information

### PURPOSE

The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational planning process to ensure independence, balance, objectivity and scientific rigor for all Continuing Medical Education (CME) activities.

### DISCLOSURE OF FINANCIAL RELATIONSHIPS

In compliance with the ACCME Standards, each individual in a position to control the content of a CME activity is required to disclose all financial relationships with ACCME defined ineligible companies. All disclosures are reviewed to identify relevant financial relationships and those are mitigated according to ACCME Standards for Integrity and Independence in Accredited Continuing Education before the individual can assume their role in the activity.

For the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022), disclosure information will be available for viewing as of September 22, 2022. Presenters are also required to include a disclosure slide listing all relevant financial relationships with ineligible companies. CME related questions should be directed to IASLC at [cme@iaslc.org](mailto:cme@iaslc.org).

### DISCLOSURE OF COMMERCIAL SUPPORT

The International Association for the Study of Lung Cancer received support for this activity from the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

### ACCME ACCREDITATION AND AMA DESIGNATION STATEMENT

The International Association for the Study of Lung Cancer (IASLC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IASLC designates this "Other Activity" (a live conference offered in hybrid format including recorded and virtual participation) for a maximum of 16 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### TARGET AUDIENCE

The IASLC 2022 North America Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer and other thoracic malignancies, including medical oncologists, thoracic

surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, physician assistants and nurses. The Conference is also designed to provide a forum for lung cancer patients and patient advocates to receive education and share their perspectives with the lung cancer community.

### LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Apply evidence-based recommendations and clinical practice guidelines to diagnose and treat patients with lung cancer and other thoracic malignancies.
2. Describe the impact of COVID-19 on lung cancer care, research, and prevention efforts.
3. Describe scientific advances in lung cancer and other thoracic malignancies.
4. Synthesize research from clinical trials and translational studies to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
5. Advocate for lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, and implementing early screening.
6. Engage and empower patients to become active participants in their treatment.

### OFFICIAL LANGUAGE

The official language of the IASLC 2022 North America Conference on Lung Cancer is English.

### DISCLAIMER

The information presented at the IASLC 2022 North America Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.





2023 Latin America  
Conference on  
Lung Cancer

JANUARY 25-27, 2023 | MONTEVIDEO, URUGUAY

# Submit Your Abstract

Showcase your research  
and contribute to discussions  
that will shape the future  
of treatments in lung cancer  
and thoracic malignancies.



#LALCA23  
[www.lalca2023.iaslc.org/call-for-abstracts/](http://www.lalca2023.iaslc.org/call-for-abstracts/)

## HOW TO RECEIVE A CME CERTIFICATE (PHYSICIANS ONLY)

Physicians are entitled to receive a CME certificate after completing the Conference evaluation survey. A link to this survey will be emailed to all attendees at the conclusion of the Conference; the survey can also be accessed from the Conference website. After submitting the survey, physicians have the option to print or save their CME certificate.

The deadline for claiming CME credits is **December 31, 2022**. Please direct any certificate inquiries to: [cme@iaslc.org](mailto:cme@iaslc.org)

## HOW TO RECEIVE A CERTIFICATE OF ATTENDANCE (NON-PHYSICIANS)

Non-physicians are entitled to receive a "Certificate of Attendance." To claim a Certificate of Attendance, non-physicians must first complete the Conference evaluation survey. A survey link will be emailed to all attendees at the conclusion of the Conference; the survey can also be accessed from the Conference website. After submitting the survey, attendees may print or save their Certificate of Attendance.

The deadline for receiving a Certificate of Attendance is **December 31, 2022**. Please direct any certificate inquiries to: [cme@iaslc.org](mailto:cme@iaslc.org)



# INFORMATION FOR SPEAKERS & ABSTRACT PRESENTERS



## Information for Speakers and Abstract Presenters

### DISCLOSURE INFORMATION

All speakers must include a slide with their financial disclosure information. Without a disclosure slide you will not be allowed to present.

### PRESENTATION SLIDE TEMPLATE

All speakers are encouraged to use the IASLC/NALC presentation slide template for their presentation.

### INVITED SPEAKERS AND ORAL PRESENTERS

All speakers are asked to be in the session room at least 15 minutes prior to the start of their session.

Please provide your presentation slides to the Speaker Preview Center, in Denver Room on the 5th Floor at least **2 hours prior to your presentation**, or as of the opening hours on Saturday, September 24. The use of personal laptops for presentations is not allowed as it can cause technical delays and cut into a presenter's time.


*No file submissions will be accepted in the session rooms.*

## Speaker Preview Center Hours

 Denver Room | 5th Floor

Saturday, September 24	<b>07:00 - 16:30</b>
Sunday, September 25	<b>07:00 - 12:00</b>

## Poster Display Time

 Chicago Ballroom FGH | 5th Floor

Saturday, September 24	<b>09:30 - 18:55</b>
Sunday, September 25	<b>09:15 - 12:30</b>

## Poster Presenters

All Poster Presentation Boards are located in the Exhibit and Poster Hall

 Chicago Ballroom FGH | 5th Floor

Each Poster Board is identified with a Poster Number that corresponds with the pre-assigned Poster Number published on the Conference website, in this Program Book as well as in the Abstract Book.

Each poster presentation will be on display for the entire duration of the Conference with an author standby time during the afternoon Poster Viewing Reception. Poster Presenters are required to stand by their poster during the designated times to answer questions from delegates.

## Presenters in Attendance

Saturday, September 24	<b>17:40 - 18:55</b>
------------------------	----------------------

## Poster Pick Up\*

 Registration Counter | 5th Floor

Saturday, September 24	<b>06:00 - 08:00</b>
------------------------	----------------------

*\*Poster Print-out order with NALC 2022 Secretariat only.*



### Poster Set Up Times

Saturday, September 24  
06:00 - 08:00

### Poster Take Down Time

Sunday, September 25  
12:30 - 13:30



# NACLC 2022


## EDUCATION AWARDS



#NACLC22

#NACLC22 | [nalc2022.iaslc.org](https://nalc2022.iaslc.org)

### NACLC 2022 Education Awards



#### Congratulations to the NACLC 2022 Education Award Winners!

Award Winners will be presented with their awards during the **Opening Session** on **Friday, September 23** from **17:30 – 18:30** in the Marriott Ballroom on the 4th Floor.

##### Eunji Choi

Stanford University School of Medicine, United States

**OA01.01:** Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked

Oral Abstract Session 01 (OA01)

**Saturday, September 24 | 15:00 – 16:40**

**Chicago Ballroom ABCD**

##### Nathaniel Deboever

The University of Texas MD Anderson Cancer Center, Department of Thoracic and Cardiovascular Surgery, United States

**PP01.06:** Circulomic Variables May Predict Pathologic Staging Preoperatively in Treatment-Naïve Non-Small Cell Lung Cancer

Poster Viewing Reception

**Saturday, September 24 | 17:40 – 18:55**

**Exhibit and Poster Hall**

##### Lei Deng

Roswell Park Comprehensive Cancer Center, United States

**PPD04.03:** Risk of Further Progression or Death among Non-small Cell Lung Cancer Patients with Durable Disease Control Enrolled in Immunotherapy Trials

Poster Discussion Session

**Saturday, September 24 | 16:40 – 17:40**

**Chicago Ballroom ABCD**

##### Lei Deng

Roswell Park Comprehensive Cancer Center, United States

**PP01.71:** Survival Outcome of Pulmonary Sarcomatoid Carcinoma Treated with Immunotherapy: A Study of National Cancer Database

Poster Viewing Reception

**Saturday, September 24 | 17:40 – 18:55**

**Exhibit and Poster Hall**

##### Donna Phan

Montefiore Medical Center, United States

**PP01.04:** Hispanic Patients are at Higher Risk for Delayed Time to Surgery Following Identification of a Solid Lung Nodule

Poster Viewing Reception

**Saturday, September 24 | 17:40 – 18:55**

**Exhibit and Poster Hall**

##### Julie Wu

Stanford University, United States

**PP01.05:** Impact of PD-L1 Status on Survival on Immunotherapy Monotherapy in Real-World Patients with Poor Performance Status: A US Nationwide Veterans Affairs Study

Poster Viewing Reception

**Saturday, September 24 | 17:40 – 18:55**

**Exhibit and Poster Hall**



[illegible][illegible]



# SCIENTIFIC SESSIONS



## Scientific Sessions

### Program at a Glance

CT	Friday September 23, 2022	Saturday September 24, 2022	Sunday September 25, 2022
6:30			
7:00			
7:30		Networking Breakfast 07:00 - 08:00	Networking Breakfast 07:00 - 08:00
8:00			
8:30		Education Session 01 (ES01): Immune Checkpoint Inhibitors - Implications for Cure 08:00 - 09:30	Education Session 04 (ES04): Implications for Immunotherapy in Subsets of Patients with Thoracic Disease 08:15 - 09:15
9:00			Education Session 05 (ES05): SCLC & Important Updates in Thoracic Oncology - Updates from WCLC 08:15 - 09:15
9:30		Poster Viewing and Networking Break 09:30 - 10:00	Poster Viewing and Networking Break 09:15 - 09:45
10:00		Education Session 02 (ES02): Medical Oncology - Targeted Therapy (including Resistance, KRAS, HER2, Toxicity, ADC) 10:00 - 11:30	Education Session 06 (ES06): Medical Oncology - Translational Science and Immunotherapy 09:45 - 11:15
10:30		Education Session 03 (ES03): Local Therapy in NSCLC 10:00 - 11:30	Education Session 07 (ES07): Screening, Early Detection and Nodule Management 09:45 - 11:15
11:00			Keynote Session 03 (KN03): Closing Keynote - The Rapid Evolution of Peri-operative Immune Therapy in NSCLC 11:15 - 12:15
11:30			
12:00		Networking Lunch 11:30 - 13:30	
12:30			Women's Forum Networking Lunch 12:30 - 13:30
13:00			
13:30		Keynote Session 02 (KN02) - Cancer Immunotherapy: Targeting Immune Dysfunctions in Tumor Sites 13:30 - 14:30	
14:00			
14:30		Networking Break 14:30 - 15:00	
15:00			
15:30		Oral Abstract Session 01 (OA01) 15:00 - 16:40	
16:00			
16:30			
17:00		Poster Discussion (PPD01) 16:40 - 17:40	
17:30	Keynote Session 01 (KN01) - Opening Keynote: Lung Cancer Care Delivery in Unprecedented Times 17:30 - 18:30		
18:00		Poster Viewing Reception 17:40 - 18:55	
18:30	Welcome Reception - CURE® Lung Cancer Heroes® Cocktail Reception 18:30 - 19:30		
19:00			
19:30			
20:00	CURE® Lung Cancer Heroes® Awards Ceremony 19:30 - 21:00		
20:30			
21:00			

Refreshments Provided IASLC CME Accredited Live Streaming Sign-up Event

<b>Registration Hours:</b>	<b>Speaker Preview Center Hours:</b>	<b>Exhibit Hours:</b>
Friday, September 23 15:30 - 19:30	Saturday, September 24 07:00 - 16:30	Saturday, September 24 09:30 - 18:00
Saturday, September 24 06:00 - 19:30	Sunday, September 25 07:00 - 12:00	Sunday, September 25 09:15 - 12:30
Sunday, September 25 06:00 - 13:00		



Friday, September 23, 2022

Keynote Session 01 (KN01) – Opening Session with Keynote Speaker

17:30 – 18:30

Marriott Ballroom | 4th Floor

Chair(s)

Karen Kelly, United States & Marina Chiara Garassino, United States

17:30 – 17:50

Welcome Remarks and Education Award Presentations

Karen Kelly, United States & Marina Chiara Garassino, United States

17:50 – 18:20

KN01:01: Lung Cancer Care Delivery in Unprecedented Times

Everett Vokes, United States

18:20 – 18:30

Q&A Discussion

Cure® Lung Cancer Heroes® Cocktail Reception

18:30 – 19:30

Halstead | 4th Floor

Light refreshments and beverages will be provided.

Cure® Lung Cancer Heroes® Awards Ceremony

19:30 – 21:00

Marriott Ballroom | 4th Floor

SIGN-UP SESSION

CURE® is proud to host the 2022 Lung Cancer Heroes® recognition ceremony, an evening of gratitude and celebration for the heroes who have made a significant impact in the lives of patients with lung cancer. Each Lung Cancer Hero is nominated by patients, caregivers, advocates or health care professionals for their heroic contributions in the field of lung cancer or in the individual lives of those living with the disease. Along with our sponsor and various advocacy groups, CURE® is bringing together the lung cancer community to end the stigma of the disease, inform, connect, and empower anyone who has been impacted.

ES	Education Session
IS	Industry Symposia
KN	Keynote Session
OA	Oral Abstract Session
PPD	Poster Discussion
WF	Women's Forum



Saturday, September 24, 2022

07:00 – 08:00 Networking Breakfast

Chicago Ballroom Foyer | 5th Floor

Education Session 01 (ES01): Immune Checkpoint Inhibitors – Implications for Cure

08:00 – 09:30

Chicago Ballroom ABCD | 5th Floor

Chair(s)

Jessica Donington, United States & Nisha Mohindra, United States

08:00 - 08:02

Welcome

Jessica Donington, United States & Nisha Mohindra, United States

08:02 - 08:12

ES01.01: Neoadjuvant or Adjuvant Therapy in NSCLC: What's the Impact?

Tina Cascone, United States

08:12 - 08:22

ES01.02: The Centrality of Pathology for the Treatment of Early Stage Disease

Aliya Husain, United States

08:22 - 08:32

ES01.03: Clinical and Biological Characteristics of Patients With MPR and CPR After Neoadjuvant

Hossein Borghaei, United States

08:32 - 08:42

ES01.04: Surgery in the Brave New World of Immunotherapy

Erin Gillaspie, United States

08:42 - 08:52

ES01.05: Longterm Follow Up After Curative Therapy (Implications for the Care Team)

Marianne Davies, United States

08:52 - 09:17

ES01.08: Case Discussion

All Speakers & Jill Feldman, United States

09:17 – 09:30

Q&A Discussion

09:30 – 10:00 Poster Viewing and Networking Break

Chicago Ballroom FGH | 5th Floor

Education Session 02 (ES02): Medical Oncology - Targeted Therapy (including Resistance, KRAS, HER2, Toxicity, ADC)

10:00 – 11:30

Chicago Ballroom ABCD | 5th Floor

Chair(s)

Frank Weinberg, United States & Jessica Lin, United States

10:00 – 10:02

Welcome

Frank Weinberg, United States & Jessica Lin, United States

10:02 - 10:12

ES02.01: How to Personalize the Treatment in Patients with KRAS G12C +KRASG12 D + G12V

Biagio Ricciuti, United States

10:12 - 10:22

ES02.02: Antibody Drug Conjugates: Target Identification and Toxicities

Sukhmani Padda, United States

10:22 - 10:32

ES02.03: Treatment of Novel Tumor Mutations (Her 2, EGFR Exon 20, METex14)

Mary Jo Fidler, United States

10:32 - 10:42

ES02.04: Treatment of Novel Fusions (NTRK, RET, CLIP1, NRG1)

Christine Bestvina, United States

10:42 - 10:52

ES02.05: Future Strategies in EGFR Mutated NSCLC

Angel Qin, United States

10:52 - 11:02

ES02.06: Best Sequence for ALK and ROS1 Inhibitors

Jessica Lin, United States

11:02 - 11:17

ES02.07: Case Discussion

All Speakers + Upal Basu Roy, United States

11:17 – 11:30

Q&A Discussion

Education Session 03 (ES03): Local Therapy in NSCLC

10:00 – 11:30

Chicago Ballroom E | 5th Floor

Chair(s)

David Odell, United States & Gaurav Marwaha, United States

10:00 – 10:02

Welcome

David Odell, United States & Gaurav Marwaha, United States

10:02 - 10:12

ES03.01: Disparities in Care for Early Stage NSCLC

Loretta Erhunmwunsee, United States

10:12 - 10:22

ES03.02: Importance of Surgical Quality

Varun Puri, United States

10:22 - 10:32

ES03.03: Evidence for Sublobar Resections

Nasser Altorki, United States





10:32 - 10:42 ES03.04: Local Consolidative Oligometastasis  
*Puneeth Iyengar, United States*

10:42 - 10:52 ES03.05: SBRT in Era of Immunotherapy  
*Pamela Samson, United States*

10:52 - 11:17 ES03.06: Case Discussion  
*All Speakers*

11:17 – 11:30 Q&A Discussion

11:30 – 13:30 **Networking Lunch**  
Chicago Ballroom Foyer | 5th Floor

**Keynote Session 02 (KN02) - Cancer Immunotherapy: Targeting Immune Dysfunctions in Tumor Sites**

13:30 – 14:30 **Chicago Ballroom ABCD | 5th Floor**  
*Chair(s)* *Jessica Donington, United States & Heather Wakelee, United States*

13:30 – 13:35 **Welcome**  
*Jessica Donington, United States & Heather Wakelee, United States*

13:35 - 14:15 KN02.01: Cancer Immunotherapy: Targeting Immune Dysfunctions in Tumor Sites  
*Lieping Chen, United States*

14:15 - 14:30 Q&A Discussion

14:30 – 15:00 **Poster Viewing and Networking Break**  
Chicago Ballroom FGH | 5th Floor

**Oral Abstract Session 01 (OA01)**

15:00 – 16:30 **Chicago Ballroom ABCD | 5th Floor**  
*Chair(s)* *Jessica Donnington, United States & Jyoti Patel, United States*

15:00 – 15:02 **Welcome**  
*Jessica Donnington, United States & Jyoti Patel, United States*

15:02 - 15:10 OA01.01: Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked  
*Eunji Choi, United States*

15:10 - 15:18 OA01.02: Smoking Recidivism in a Low Dose Lung Cancer Screening Program Despite Point of Care Counseling  
*Lauren Johnson, United States*

15:18 - 15:26 OA01.03: Discussant  
*James Mulshine, United States*

15:26 - 15:32 Q&A Discussion

15:32 - 15:40 OA01.04: First-Line Nivolumab + Ipilimumab + Chemotherapy in Metastatic NSCLC: CheckMate 9LA 3-Year Update  
*David Paul Carbone, United States*

15:40 - 15:48 OA01.05: Three-year Outcomes per PD L1 Status and Continued Cemiplimab Beyond Progression + Chemotherapy: EMPOWER-Lung 1  
*Mustafa Özgüroğlu, Istanbul*

15:48 - 15:56 OA01.06: Discussant  
*Greg Durm, United States*

15:56 - 16:02 Q&A Discussion

16:02 - 16:10 OA01.07: Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations  
*Lyudmila Bazhenova, United States*

16:10 - 16:18 OA01.08: Clinical Response to Tepotinib According to Circulating Tumor (ct)DNA Biomarkers in Patients with Advanced Metastatic NSCLC with High-level MET Amplification (METamp) Detected by Liquid Biopsy (LBx)  
*Xiuning Le, United States*

16:18 - 16:26 OA01.09: Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Updated ADAURA Results  
*Roy Herbst, United States*

16:26 - 16:34 OA01.10: Discussant  
*Joshua Sabari, United States*

16:34 - 16:40 Q&A Discussion

**Poster Discussion (PPD01)**

16:40 – 17:40 **Chicago Ballroom ABCD | 5th Floor**  
*Chair(s)* *DuyKhanh Ceppa, United States & Hedy Lee, Kindler, United States*

16:40 - 16:55 PPD01.03 Discussant  
*Melanie Smith, United States*

PPD01.01: Patterns of Use of Medical Cannabis in Lung Cancer and Other Cancer Patients  
*Deepti Behl, United States*

PPD01.02: Identifying Physical, Social, Emotional, and Medical Needs of Lung Cancer Survivors with Advanced Non-Small Cell Lung Cancer  
*Mattea Miller, United States*

16:55 - 17:10 PPD02.04: Discussant  
*Jyoti Patel, United States*

PPD02.01: Comprehensive Genomic Profiling (CGP) for Diagnostic Clarity in Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC)  
*Umit Tapan, United States*

PPD02.02: Tepotinib + Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification (METamp): Final Analysis of INSIGHT  
*Richard OHara, United States*

PPD02.03: Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Analysis of All Patients From VISION Cohorts A and C  
*Marina Chiara Garassino, United States*

17:10 – 17:20 PPD03.02: Discussant  
*Mohamed Abazeed, United States*

PPD03.01: Adjuvant Radiation Therapy in Clinical Stage III (N2) Non-Small Cell Lung Cancer after Neoadjuvant Chemotherapy  
*Takefumi Komiya, United States*

17:20 – 17:40 PPD04.04: Discussant  
*Johnathan Riess, United States*

PPD04.01: Survival Associations of T Cell Clusters with Immunotherapy in Mesothelioma  
*Aakash Desai, United States*

PPD04.02: First-Line Nivolumab + Ipilimumab (NIVO+IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227  
*Hossein Borghaei, United States*

PPD04.03: Risk of Further Progression or Death Among Non Small Cell Lung Cancer Patients with Durable Disease Control Enrolled in Immunotherapy Trials  
*Lei Deng, United States*

17:40 – 18:55 **Poster Viewing Reception**  
Chicago Ballroom FGH | 5th Floor

LIVE STREAMING


IASLC CME ACCREDITED

REFRESHMENTS PROVIDED




Sunday, September 25, 2022

07:00 – 08:00    **Networking Breakfast**      
Chicago Ballroom Foyer | 5th Floor

**Education Session 04 (ES04):** Implications for Immunotherapy in Subsets of Patients with Thoracic Disease    

- 08:15 – 09:15    **Chicago Ballroom ABCD | 5th Floor**  
Chair(s)    *Young Kwang Chae, United States & Heather Wakelee, United States*
- 08:15 – 08:17    **Welcome**  
*Young Kwang Chae, United States & Heather Wakelee, United States*
- 08:17 – 08:27    **ES04.01: New Era for Mesothelioma**  
*Aaron Mansfield, United States*
- 08:27- 08:37    **ES04.02: 2022 Primer on Thymoma and Thymic Carcinoma**  
*Nisha Monhindra, United States*
- 08:37 – 08:47    **ES04.03: Immunotherapy in Older Patients with Lung Cancer**  
*Carolyn Presley, United States*
- 08:47 – 08:57    **ES04.04: Risk Factors for Immune Related Adverse Events: Implication for Identification and Early Intervention**  
*Balazs Halmos, United States*
- 08:57 – 09:07    **ES04.05: Considerations for Duration and De-escalation of Immunotherapy**  
*Ryan Gentzler, United States*
- 09:07 – 09:15    **Q&A Discussion**

**Education Session 05 (ES05):** SCLC and Important Updates in Thoracic Oncology - Updates from WCLC    

- 08:15 – 09:15    **Chicago Ballroom E | 5th Floor**  
Chair(s)    *Greg Durm, United States & Jill Feldman, United States*
- 08:15 – 08:17    **Welcome**  
*Greg Durm, United States & Jill Feldman, United States*
- 08:17 – 08:27    **ES05.01: First Line Treatment for Extensive Stage SCLC**  
*Siddhartha Devarakonda, United States*
- 08:27 – 08:37    **ES05.02: New Agents for Second and Further Lines**  
*Saiama Waqar, United States*

- 08:37 – 08:47    **ES05.03: The Evolving Role of Radiotherapy in SCLC**  
*Aditya Juloori, United States*
- 08:47 – 08:57    **ES05.04: Case Study for Limited Stage**  
*Shruti Patel, United States*
- 08:57 – 09:15    **Q&A Discussion**

09:15 – 09:45    **Poster Viewing and Networking Break**      
Chicago Ballroom FGH | 5th Floor


**Education Session 06 (ES06):** Medical Oncology - Translational Science and Immunotherapy    

- 09:45 – 11:15    **Chicago Ballroom E | 5th Floor**  
Chair(s)    *Mohamed Abazeed, United States & Lecia Sequist, United States*
- 09:45 – 09:47    **Welcome**  
*Mohamed Abazeed, United States & Lecia Sequist, United States*
- 09:47 – 10:02    **ES06.01: Optimal Frontline Therapy for Immunotherapy**  
*Marina Chiara Garassino, United States*
- 10:02 – 10:17    **ES06.02: New Strategies to Overcome Immune Checkpoint Resistance**  
*John Wrangle, United States*
- 10:17 – 10:32    **ES06.03: LKB1 and KEAP1, Prognostic or Predictive Factors?**  
*Ferdinandos Skoulidis, United States*
- 10:32 – 10:47    **ES06.04: Role of Liquid Biopsy for Early Diagnosis**  
*Lecia Sequist, United States*
- 10:47 – 11:02    **ES06.05: Role of Liquid Biopsy in Monitoring Progression**  
*Christian Rolfo, United States*
- 11:02 – 11:15    **Q&A Discussion**


**Education Session 07 (ES07):** Screening, Early Detection and Nodule Management    

- 09:45 – 11:15    **Chicago Ballroom ABCD | 5th Floor**  
Chair(s)    *John Ferguson, United States & Septimiu Murgu, United States*
- 09:45 – 09:47    **Welcome**  
*John Ferguson, United States & Septimiu Murgu, United States*

- 09:47 – 09:57    **ES07.01: Updates and Challenges in Lung Cancer Screening (Not Disparities)**  
*Betty Tong, United States*
- 09:57 – 10:07    **ES07.02: Health Disparities in High Risk Lung Cancer Screening Patients**  
*Anand Narayan, United States*
- 10:07 – 10:17    **ES07.03: Role of Endoscopic Technology in Nodule Management**  
*Janani Reisenauer, United States*
- 10:17 – 10:27    **ES07.04: Role of Robotics in Nodule Management**  
*Lana Schumacher, United States*
- 10:27 – 10:37    **ES07.05: The Role of Biomarkers in the Evaluation of the Screen-Detected Nodule**  
*Sonali Sethi, United States*
- 10:37 – 10:47    **ES07.06: Optimizing Tobacco Treatment for People Seeking Lung Cancer Care**  
*Brian Hitsman, United States*
- 10:47 – 11:02    **ES07.07: Case Discussion**  
*Carrie Barth, United States*
- 11:02 – 11:15    **Q&A Discussion**

**Keynote Session 03 (KN03):** Closing Keynote - The Rapid Evolution of Peri-operative Immune Therapy in NSCLC    

- 11:15 – 12:15    **Chicago Ballroom ABCD | 5th Floor**  
Chair(s)    *Jessica Donington, United States*
- 11:15 – 11:20    **Welcome**  
*Jessica Donington, United States*
- 11:20 – 12:00    **KN03.01: The Rapid Evolution of Peri-operative Immune Therapy in NSCLC**  
*Heather Wakelee, United States*
- 12:00 – 12:15    **Q&A Discussion**

**Women’s Forum Networking Lunch (WF01)**      
*Lunch Provided*

- 12:30 – 13:30    **Chicago Ballroom ABCD | 5th Floor**
- 12:30 – 13:30    **WF01.01: Women’s Forum Networking Lunch Panel**  
*Karen Kelly, United States, Heather Wakelee, United States, Jessica Donington, United States, Marina Chiara Garassino, United States & Jyoti Patel, United States*

 LIVE STREAMING

 IASLC CME ACCREDITED

 REFRESHMENTS PROVIDED



# POSTER SESSIONS



## Poster Sessions

📍 Exhibit and Poster Hall | Chicago Ballroom FGH | 5th Floor

- PP01.01 **PEOPLE (NTC03447678), a Phase II Trial to Test Biomarkers of Response to Pembrolizumab as First-Line Treatment in Advanced NSCLC Patients with PD-L1>50%.**  
*Marina Chiara Garassino, United States*
- PP01.02 **Molecular Recurrence Risk Profiles in Patients with Early-Stage NSCLC: Current Standard of Care Compared to a Prognostic and Predictive 14-gene Expression Assay**  
*Julie Hufham, United States*
- PP01.03 **Flagging High-Risk Individuals with a ML Model Improves NSCLC Early Detection in a USPSTF-Eligible Population**  
*Eran Netanel Choman, Israel*
- PP01.04 **Hispanic Patients are at Higher Risk for Delayed Time to Surgery Following Identification of a Solid Lung Nodule**  
*Donna Phan, United States*
- PP01.05 **Impact of PD-L1 Status on Survival on Immunotherapy Monotherapy in Real-World Patients with Poor Performance Status: A US Nationwide Veterans Affairs Study**  
*Julie Wu, United States*
- PP01.06 **Circulomic Variables may Predict Pathologic Staging Preoperatively in Treatment-Naïve Non-Small Cell Lung Cancer**  
*Nathaniel Deboever, United States*
- PP01.07 **Identifying Patient Barriers to Adherence in Lung Cancer Screening**  
*April Plank, United States*
- PP01.08 **Circulating Genetically Abnormal Cells Predicts Risk of Lung Cancer in Individuals with Indeterminant Pulmonary Nodules**  
*Benjamin A Katchman, United States*
- PP01.09 **Genotypic Characteristics and Resistance Mutations in Advanced ALK+ NSCLC: The ALK-PATHFINDER Study**  
*Santiago Ponce Aix, Spain*
- PP01.10 **A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory (R/R) NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)**  
*Jonathan Riess, United States*
- PP01.11 **Furmonertinib is an Oral, Irreversible, Highly Brain-Penetrant Pan-EGFR Inhibitor with Activity Against Classical and Atypical EGFR Mutations**  
*Luna Musib, United States*
- PP01.12 **Increasing Diagnosis of Ground Glass Nodules and Semi-Solid Lung Lesions on Chest CT Scans over the Past Decade**  
*Gavitt Woodard, United States*
- PP01.13 **Low Screening Rates in Patients Ultimately Diagnosed with Advanced NSCLC**  
*Joseph Fuchs, United States*
- PP01.14 **The Utilization of Molecular Risk Stratification of Early-Stage Non-Small Cell Lung Cancer to Identify Increase Failure Despite Complete Surgical Resection**  
*K Adam Lee, United States*
- PP01.15 **Circulating Tumor DNA (ctDNA) Level: a Prognostic Biomarker for Clinical Outcomes in Non-Small Cell Lung Cancer (NSCLC) Patients Across Diverse Therapy Classes**  
*Layla Mowlavi, United States*
- PP01.16 **Improving Access to Early Palliative Care Delivery for Patients with an Advanced Thoracic Malignancy Through an Embedded Onco-Palliative Clinic Model**  
*Carolyn Presley, United States*



PP01.17	<b>Sotorasib in Advanced KRAS p.G12C–Mutated NSCLC with Treated or Untreated Brain Metastases: Safety and Efficacy Data from the Global Expanded Access Program (EAP)</b> <i>Jessica Bauman, United States</i>
PP01.18	<b>Surgical Resection after Targeted Therapy in Stage IV NSCLC: Nuances and Considerations</b> <i>Mara Antonoff, United States</i>
PP01.19	<b>Volatile Organic Compound Biomarkers Identification for Prediction of Lung Cancer Based on Exhaled Breath Analysis</b> <i>Yoohwa Hwang, Republic of Korea</i>
PP01.20	<b>Trial in Progress: Screening for High Frequency Malignant Disease (SHIELD)</b> <i>Lindsey Cotton, United States</i>
PP01.21	<b>Utilization of Pre- and Post-Stereotactic Body Radiotherapy (SBRT) Neutrophil-to-Lymphocyte (NLR) Ratios and Platelet-to-Lymphocyte (PLR) Ratios as Prognostic Factors in Early-Stage Non-Small Cell Lung Cancer</b> <i>Neha Sharma, United States</i>
PP01.22	<b>First Lung Cancer Screening Program in Greece - Initial Experience, Preliminary Data and Pitfalls.</b> <i>Nikolaos Koufos, Greece</i>
PP01.23	<b>Outcomes of Stage IIIA Disease in NSCLC, Treated with Surgery - A Single Institution Experience</b> <i>Prafullkumar G Gamit, India</i>
PP01.24	<b>5-Year Survival Outcomes of Lung Cancer Treated with Surgery: A Single Institution Experience</b> <i>Prafullkumar G Gamit, India</i>
PP01.25	<b>Incidence and Timing of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor as Monotherapy or in Combination With Chemotherapy</b> <i>Austin Secor, United States</i>
PP01.26	<b>Evaluation of Automated Sample Preparation System for Lymph Node Sampling</b> <i>Jennifer Duke, United States</i>
PP01.27	<b>Real-World Effectiveness of Second-Line Therapies for Metastatic Non-Small Cell Lung Cancer</b> <i>Lyudmila Bazhenova, United States</i>
PP01.28	<b>Tumor Engraftment is Prognostic for Disease Recurrence in Resected Non-Small Cell Lung Cancer</b> <i>Bindiya G. Patel, United States</i>
PP01.29	<b>Prevalence and Predictor of Significant Unmet Needs in Patients who were Surgically Resected for Non Small Cell Lung Cancer</b> <i>Junhee Park, Republic of Korea</i>
PP01.30	<b>Are Delays In The Diagnosis Of Lung Cancer Due To Patients First Seeking Treatment for Tuberculosis In Rural India?</b> <i>Sasmith Menakuru, United States</i>
PP01.31	<b>Real-World Treatment Outcomes of Amivantamab in Pre-Approval Access (PAA) Participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations (ex20ins)</b> <i>Joshua Sabari, United States</i>
PP01.32	<b>Proteasome Hyperactivity as a Targetable Vulnerability in Oncogenic Missense TP53 Mutated NSCLC.</b> <i>Eziafa Oduah, United States</i>
PP01.33	<b>Serum Autoantibodies may help Identify Individuals with Actionable Pulmonary Nodules on LDCT Scan.</b> <i>Claire Auger, United States</i>
PP01.34	<b>Induction of Tertiary Lymphoid Structures in Non-Small Cell Lung Cancer Improves B and T Cell Anti-Tumor Immunity</b> <i>Hye Mi Kim, United States</i>
PP01.35	<b>Validation of a High-Specificity Blood-Based Autoantibody Test to Detect Lung Cancer in Pulmonary Nodules</b> <i>Trevor Pitcher, United States</i>

PP01.36	<b>Blood-Based Biomarker Testing in Advanced Non-Small Cell Lung Cancer: Adoption, Biomarker Assessment, and Therapy Selection</b> <i>Katherine T. Lofgren, United States</i>
PP01.37	<b>Quality of Life in Non-Small Cell Lung Cancer Patients With Brain/CNS Metastases– Real-World Evidence</b> <i>Stan Krulewicz, United States</i>
PP01.38	<b>Biomarker Testing and Associated Treatment patterns in Advanced Non-Small Cell Lung Cancer in the US</b> <i>Stan Krulewicz, United States</i>
PP01.39	<b>Infrastructure for Interobserver Variability Assessment of Pathologic Response (PR), in Surgical Resection Specimens Following Neoadjuvant Immune Check Point Inhibitor (ICI) Therapies in Early Stage NSCLC</b> <i>Neus Bota-Rabassedas, United States</i>
PP01.40	<b>Target Lesion Response and Outcomes in Patients Treated with Brigatinib vs Crizotinib in ALTA-1L</b> <i>Pingquan Zhang, United States</i>
PP01.41	<b>Efficacy of Sotorasib Versus Standard Chemotherapy + Immunotherapy in KRAS G12C Mutated Lung Cancer: A Comparative Study Modeling Real-World Data</b> <i>Philip Haddad, United States</i>
PP01.42	<b>Efficacy of Adagrasib Versus Standard Chemotherapy +/- Immunotherapy in KRAS G12C Mutated Lung Cancer: A Comparative Study Modeling Real-World Data</b> <i>Philip Haddad, United States</i>
PP01.43	<b>A Retrospective Single-Center Analysis of Patients with Atypical EGFRm NSCLC Treated with First-Line EGFR-TKIs</b> <i>Xiuning Le, United States</i>
PP01.44	<b>Long-Term Survival and Outcomes by Race from the Phase I/II trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced NSCLC: HCRN LUN13-175</b> <i>Ryan Gentzler, United States</i>
PP01.45	<b>Implementation Challenges and Disparities in Molecular Testing for Patients with NSCLC at a Safety-Net Hospital</b> <i>Laura Burns, United States</i>
PP01.46	<b>Unfiltered Patient Insights: Experiences of Patients With ALK+ or EGFR Exon20 Insertion+ Non-Small Cell Lung Cancer</b> <i>Kim Gibbs, United States</i>
PP01.47	<b>HERTHENA-Lung02: A Randomized Phase 3 Study of Patritumab Deruxtecan vs Platinum-Based Chemotherapy in Locally Advanced or Metastatic EGFR-Mutated NSCLC After Progression with a Third Generation EGFR TKI</b> <i>Balazs Halmos, United States</i>
PP01.48	<b>Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) without EGFR-Activating Mutations</b> <i>Melissa L. Johnson, United States</i>
PP01.49	<b>Analysis of Outcomes by Race in Patients with Advanced NSCLC</b> <i>Danielle Dressler, United States</i>
PP01.50	<b>EMERGE-201: Phase 2 Basket Study of Lurbinectedin Monotherapy in Advanced or Metastatic Solid Tumors</b> <i>Debasis Chakrabarti, United States</i>
PP01.51	<b>Cost-Efficiency and Budget-Neutral Expanded Access Modeling of Toripalimab over Pembrolizumab in Advanced NSCLC</b> <i>Karen MacDonald, United States</i>
PP01.52	<b>Budget Impact Analysis of Toripalimab Versus Pembrolizumab in Previously Untreated Advanced Squamous NSCLC</b> <i>Karen MacDonald, United States</i>
PP01.53	<b>Pathologic Response Assessment Tool – Architecting a Cloud-Based Tool to Streamline Logistics for Shipping, Tracking, Scoring, and Reporting.</b> <i>Juan Posadas Ruiz, United States</i>



PP01.54	<b>ImmunoBlood: A Prospective Study Evaluating the Development of Anti-Checkpoint Inhibitor Antibodies in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy</b> <i>Corrado Orciuolo, Italy</i>
PP01.55	<b>Real-World Treatment Sequencing and Impact on Outcomes in ALK-Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC)</b> <i>Yin Wan, United States</i>
PP01.56	<b>Peripheral T-Cell Receptor Repertoire Dynamics in Patients with Small Cell Lung Cancer</b> <i>Meridith L Balbach, United States</i>
PP01.57	<b>Evaluation of the Metabolism of the Biogenic Amines on the Neuroendocrine Differentiation of A549 Adenocarcinoma Cells</b> <i>Irasema Mendieta, Mexico</i>
PP01.58	<b>Multi City Opportunistic Screening of Lung Nodules amidst COVID-19</b> <i>Ankit Modi, India</i>
PP01.59	<b>Performance of a Deep Learning Algorithm for the Early Detection of Malignant Lung Nodules</b> <i>Anish Chhapparwal, India</i>
PP01.60	<b>Double the Lung Cancer Early Detection Rates with Incidental Lung Nodule Program</b> <i>William Mayfield, United States</i>
PP01.61	<b>First-Line Treatment Patterns of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) with and without BRAF Mutations in the US</b> <i>Maria Cecilia Vieira, United States</i>
PP01.62	<b>Therapeutic Potential of Folate Conjugated Actinonin Encapsulated Human Serum Albumin Nanoformulation Against Lung Adenocarcinoma Model.</b> <i>Priyanca Ahlawat, India</i>
PP01.63	<b>Real-World Assessment of Clinical Outcomes Associated with Immunotherapy (IO) and chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients with Brain Metastases and METexon14 Skipping Mutations Treated in US Community Centers</b> <i>Beilei Cai, United States</i>
PP01.64	<b>A Safety and Efficacy Analysis Comparing Elderly vs Nonelderly Patients Treated with Consolidation Immunotherapy after Chemoradiation for stage III NSCLC from the BTCRC LUN 16-081 Clinical Trial</b> <i>Shobha Shahani, United States</i>
PP01.65	<b>Treatment Patterns of Malignant Pleural Mesothelioma in a Resource Limited Setting: A “Real World” Study</b> <i>Karina Morales Hernández, Mexico</i>
PP01.66	<b>A Case of Metastatic HER2-Amplified Non-Small-Cell Lung Cancer (NSCLC) Treated with Trastuzumab Deruxtecan</b> <i>Karen Yun, United States</i>
PP01.67	<b>Decentralized, Real-World Study of Afatinib in Patients with Advanced/Metastatic Solid Tumors with NRG1 Fusions</b> <i>Stephen Liu, United States</i>
PP01.68	<b>Registry Based Analysis of Radiation Modality on Survival with Definitive Chemoradiation for Stage III Non Small Cell Lung Cancer (NSCLC)</b> <i>Andrew Gross, United States</i>
PP01.69	<b>NSCLC with Testicular Metastasis: A Case Report</b> <i>Anna-Lena Meinhardt, United States</i>
PP01.70	<b>Prevalence, Treatment Patterns, and Survival by Age in Patients Diagnosed with Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Brain Metastases (BM) in the USA</b> <i>Melissa Laurie, United States</i>
PP01.71	<b>Survival Outcome of Pulmonary Sarcomatoid Carcinoma Treated with Immunotherapy: A Study of National Cancer Database</b> <i>Lei Deng, United States</i>

PP01.72	<b>Cell-free DNA for Treatment Response and Recurrence Monitoring in Advanced Stage Lung Cancer</b> <i>Stephen Yu, United States</i>
PP01.73	<b>Time from Biopsy to Treatment Initiation at an Academic Hospital and Affiliate Hospitals: Overall Survival Analysis</b> <i>Chetan Vakkalagadda, United States</i>
PP01.74	<b>Clinical Validation of a Promising New Amplicon-Based Liquid Biopsy Platform for Detection of Guideline Recommended Biomarkers in Metastatic NSCLC</b> <i>Richa Dawar, United States</i>
PP01.75	<b>Neuro-Cognitive Effects of WBRT and HS-PCI in LS-SCLC</b> <i>Suryakanta Acharya, India</i>
PP01.76	<b>Lurbinectedin vs an External Control Arm in Patients with Small Cell Lung Cancer</b> <i>Xue Wang, United States</i>
PP01.77	<b>EMERGE 402: Real-world Characteristics and Safety of Lurbinectedin in Small-cell Lung Cancer (SCLC)</b> <i>Firas Badin, United States</i>
PP01.78	<b>Brain Metastasis in Patients With KRAS Mutant Advanced NSCLC Receiving Docetaxel: Pooled Clinical Trial Data Analysis</b> <i>Sukhmani Padda, United States</i>
PP01.79	<b>ALK Positive, Inc - Patient Advocacy Accelerating Research and Clinical Trials Worldwide</b> <i>Scott Schell, United States</i>
PP01.80	<b>Long Term Results of VATS Lobectomy for Early Staged Non Small Cell Lung Cancer</b> <i>Do Kim Que, Viet Nam</i>



# POSTER DISCUSSIONS



## Poster Discussions

Chicago Ballroom ABCD | 5th Floor | 16:40 - 17:40

- PPD01.01**     **Patterns of Use of Medical Cannabis in Lung Cancer and Other Cancer Patients**  
*Deepti Behl, United States*
- PPD01.02**     **Identifying Physical, Social, Emotional, and Medical Needs of Lung Cancer Survivors with Advanced Non-Small Cell Lung Cancer**  
*Mattea Miller, United States*
- PPD02.01**     **Comprehensive Genomic Profiling (CGP) for Diagnostic Clarity in Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC)**  
*Umit Tapan, United States*
- PPD02.02**     **Tepotinib + Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification (METamp): Final Analysis of INSIGHT**  
*Richard OHara, United States*
- PPD02.03**     **Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Analysis of All Patients From VISION Cohorts A and C**  
*Marina Chiara Garassino, United States*
- PPD03.01**     **Adjuvant Radiation Therapy in Clinical Stage III (N2) Non-Small Cell Lung Cancer after Neoadjuvant Chemotherapy**  
*Takefumi Komiya, United States*
- PPD04.01**     **Survival Associations of T Cell Clusters with Immunotherapy in Mesothelioma**  
*Aakash Desai, United States*
- PPD04.02**     **First-Line Nivolumab + Ipilimumab (NIVO+IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227**  
*Hossein Borghaei, United States*
- PPD04.03**     **Risk of Further Progression or Death among Non-small Cell Lung Cancer Patients with Durable Disease Control Enrolled in Immunotherapy Trials**  
*Lei Deng, United States*



# ABSTRACT AUTHOR INDEX

#NACLC22 | [nacalc2022.iaslc.org](http://nacalc2022.iaslc.org)

## Abstract Author Index

### A

Abraham, Ivo PP01.51, PP01.52  
Acharya, Suryakanta PP01.75  
Agahi, Alireza PPD04.01  
Agne, Julia PP01.16  
Agnelli, Luca PP01.01  
Ahlawat, Priyanka PP01.62  
Ahmad, Azura Rozila PPD02.02  
Ahmed, Sara PP01.05  
Ahn, Myung-Ju PP01.40, PPD02.03  
Akella, Lalith PP01.10  
Al Omari, Omar PP01.45  
Albarmawi, Husam PP01.36  
Albert, Katherine PP01.10  
Altan, Mehmet PP01.18  
Althouse, Sandra PP01.64  
Alvord, Trevor PP01.76  
Antonoff, Mara PP01.06, PP01.18  
Aptekar, Jacob PP01.78  
Ardito-Abraham, Christine PP01.17  
Aredo, Jacqueline OA01.01  
Arnaoutakis, Konstantinos PP01.55  
Arnold Egloff, Shanna A. PP01.63  
Arriola, Edurne PP01.17  
Attwood, Kristopher PP01.71  
Audigier-Valette, Clarisse PPD04.02  
Auger, Claire PP01.33  
Aversano, Jennifer PP01.02  
Awad, Mark M. PP01.17  
Axelrod, Margaret L PP01.56  
Azkárate, Aitor PP01.17

### B

Baas, Paul PPD04.01  
Backhus, Leah OA01.01  
Baden, Lara PP01.08  
Bader, Anna PP01.12  
Badin, Firas PP01.77  
Baggstrom, Maria PP01.28  
Baik, Christina S. PP01.48  
Bailey, Hollie PP01.37, PP01.38  
Bailey, Morgan PP01.26  
Bal, Amanjit PP01.62  
Balbach, Meridith L PP01.56  
Balko, Justin PP01.56  
Bankhead, Armand PP01.56  
Barneto Aranda, I. PP01.09  
Barone, Claudia OA01.02  
Barton, Colin PP01.79  
Bauman, Jessica PP01.17  
Bayona Antón, C. PP01.09  
Bazhenova, Lyudmila OA01.07, PP01.27, PP01.66  
Behl, Deepti PPD01.01

Beirat, Amir  
Benedict, Jason  
Ben-Joseph, Rami  
Benjumea, Darrin  
Bennouna, Jaafar  
Berg, Courtney  
Berghoff, Karin  
Bernabe Caro, Reyes  
Bernabé Caro, R.  
Bertino, Erin PP01.16, PP01.25  
Berumen, Laura Cristina  
Bharati, Sachidanand Jee

Bhatt, Kamalnayan  
Biswas, Tithi PP01.21, PP01.68  
Blasberg, Justin  
Bluestone, Alex  
Blum, Steven I. PPD04.02  
Blumenfrucht, Marvin PP01.69  
Boccuti, Anne PP01.76, PP01.77  
Boffa, Daniel PP01.12  
Bondarenko, Igor OA01.05  
Borad, Mitesh PPD04.01  
Borczuk, Alain PP01.39  
Borghaei, Hossein PPD04.02  
Borgia, Jeffrey PP01.33  
Bosch Barrera, J. PP01.09  
Bota-Rabassedas, Neus PP01.39, PP01.53

Boulanger, Mary  
Boumber, Yanis

Brahmer, Julie R.  
Brandi, Martina  
Brich, Silvia  
Brisbin, Lorraine  
Brock, Graham  
Brophy, Mary  
Brown, Ashely  
Bruno, Tullia  
Bruns, Rolf

Burlison, Helen  
Burns, Laura  
Bushong, Judith  
Bustamante Alvarez, Jean

### C

Cabrera-Galvez, Carlos  
Cai, Beilei PP01.27, PP01.63  
Cai, Donghong  
Cai, George  
Calamia, Matthias  
Califano, Raffaele  
Camidge, D Ross

PP01.30 Camidge, D. Ross  
PP01.16 Canali, Laura  
PP01.76 Cappuzzo, Federico  
PP01.61 Carbone, David  
OA01.04 Carbone, David Paul  
PP01.69 Carney, Jennifer  
PPD02.03 Caro, Nydia  
PPD04.02 Carpano, Silvia  
PP01.09 Carrizo Mijarra, N.  
PP01.57 Ceddia, Serena  
PP01.23, PP01.24 Chae, Young  
Chae, Young Kwang PP01.13, PP01.49, PP01.73

PP01.50 Chaires Navarro, Geraldine  
PP01.21, PP01.68 Chakrabarti, Debasis  
PP01.12 Challa, Vikas  
PP01.26 Chandrasekar, Sanjana  
PPD04.02 Chang, Gee-Chen  
PP01.69 Chang, Victor  
PP01.12 Chawla, Sanya  
OA01.05 Chen, Hongbin  
PPD04.01 Cheng, Grace  
PP01.39 Cheng, Iona  
PPD04.02 Cheng, Ying OA01.04, OA01.07, PPD02.02

PP01.09 Cheville, John PPD04.01  
PP01.39, PP01.53 Chhparwal, Anish  
PP01.53 Chioda, Marc  
PPD01.02 Chiu, Chao-Hua  
PP01.13, PP01.49, PP01.73 Cho, Byoung Chul  
PP01.73 Cho, Juhee  
PPD04.02 Choi, Eunji  
PP01.54 Choman, Eran Netanel  
PP01.01 Chouhan, Rohit  
PP01.63 Chuang, Han-Yu  
PP01.50 Chudgar, Neel  
PP01.05 Chung, Jin-Haeng  
PP01.08 Cicin, Irfan  
PP01.34 Ciuleanu, Tudor-Eliade

OA01.04, PPD04.02  
PPD02.03 Cobo-Dols, Manuel  
PP01.37, PP01.38 Colarusso, Chiara  
PP01.45 Connolly, Casey  
PPD04.02 Conti, Laura  
PP01.72 Cooper, Wendy  
Corrigan, June  
Cortot, Alexis B.  
Cotoco, Jasmin  
Cotton, Lindsey

### D

PP01.52 Dacic, Sanja  
PP01.40 D'Agostino Jr., Ralph  
PP01.40 Dakhil, Shaker



NACLC 2022   Conference Program Book					
Danese, Mark	PP01.70	Fan, Yun	OA01.07	Gould, Michael K	PP01.03
Dao, Thang	PP01.59	Fang, Jian	OA01.07	Govindan, Ramaswamy	PP01.28
Das, Millie	PP01.05	Feeney, Kynan	OA01.04	Govindarajan, Arunkumar	PP01.58
Das, Parthib	PP01.25	Feinberg, Bruce	PP01.27	Goyal, Ravi K.	PP01.63
Davies, Sherri R.	PP01.28	Feldon, Jerome	PP01.14	Griesinger, Frank	PP01.40
Davis, Keith L.	PP01.63	Feliciano, Joy	PPD01.02	Grogan, Madison	PP01.16, PP01.25
Dawar, Richa	PP01.74	Felip, Enriqueta	PP01.40, PP01.48,	Gross, Andrew	PP01.68
Dawodu, Gbalekan	PP01.04		PPD02.03	Gullo, Giuseppe	OA01.05
De Castro, Javier	PP01.17	Ferarra, Roberto	PP01.01	Gumus, Mahmut	OA01.05
De Jesús Hernández, Dulce Angelica		Ferreira, Carlos Gil	PP01.17	Guo, Janet	PP01.25
	PP01.65	Ferrell, Brandon	PP01.04	Guo, Jiannan	PP01.56
Deboever, Nathaniel	PP01.06,	Ferrer Sánchez, I.	PP01.09	Guo, Matthew	PPD01.02
	PP01.18	Fiji, Gayle	PP01.10	Gupta, Ravi G.	PPD04.02
Delmonte, Angelo	PP01.40	Fillmore, Nathanael	PP01.05		
Deng, Lei	PP01.71, PPD04.03	Foley, Grace	PP01.37, PP01.38	<b>H</b>	
Deo, Suryanarayana	PP01.23,	Forshaw, Cameron	PP01.37, PP01.38	Haddad, Philip	PP01.41, PP01.42
	PP01.24	Franklin, Patricia	OA01.02	Haddad, Tyler	PP01.25
Derrien Ansquer, Valerie	PP01.63	Friedmann, Patricia	PP01.04	Hall, Richard	PP01.44
Desai, Aakash	PPD04.01	Frohn, Claas	PP01.67	Halmos, Balazs	PP01.47, PP01.77
Detterbeck, Frank	PP01.12	Frost, Michael	PP01.63	Hammoud, Dalia	PP01.41, PP01.42
Devarakonda, Siddhartha	PP01.28	Fuang, Ho Gwo	OA01.05	Han, Ji-Youn	PP01.40
Dhanasopon, Andrew	PP01.12	Fucci, Cecilia	PP01.54	Han, Summer	OA01.01, PP01.05
Dhillon, Vijaypal	PP01.30	Fuchs, Joseph	PP01.13	Hanna, Nasser	PP01.44, PP01.64
Dimou, Anastasios	PP01.55	Fuchs, Joseph R.	PP01.49	Hanvesakul, Raj	PP01.77
Disselhorst, Maria	PPD04.01	Fujimoto, Junya	PP01.39	Harrington, Douglas	PP01.02
Do, Nhan	PP01.05	Fusco, Francesca	PP01.54	Hartley, Christopher	PP01.26
Doleshal, Martina	PP01.02			Hayashi, Hidetoshi	PP01.48
Dolezal, James	PP01.01	<b>G</b>		He, Kai	PP01.25
Donovan, Michael J	PP01.08	Gadgeel, Shirish	PP01.10	He, Xuanyao	OA01.05
Dressler, Danielle	PP01.13, PP01.49,	Galsky, Matthew D.	PP01.50	Heeke, Arielle L.	PP01.50
	PP01.73	Gamit, Prafullkumar G	PP01.23,	Helenowski, Irene	PP01.44
Du, Robyn	PP01.43		PP01.24	Hendershot, Jacob	PP01.78
Duke, Jennifer	PP01.26	Gandhi, Saumil	PP01.18	Henschke, Claudia I	PP01.08
Duncan, Kirsten	PP01.37, PP01.38,	Ganti, Apar Kishor	PP01.76	Herbst, Roy	OA01.09
	PP01.61	Ganzinelli, Monica	PP01.01	Hernández Castillo, Marco Antonio	
Durm, Greg	PP01.64	Garassino, Marina Chiara	OA01.05,		PP01.65
Dvorkin, Mikhail	OA01.05		PP01.01, PPD02.03	Herpers, Matthias	PP01.67
Dwivedi, Era	PP01.58	Garcia Campelo, Maria Rosario		Herzog, Brett	PP01.28
Dy, Grace	PPD04.03		PP01.40	Heymach, John	PP01.18
		García Campelo, R.	PP01.09	Heymach, John V.	PP01.43
<b>d</b>		García-Alcocer, Guadalupe	PP01.57	Hirsch, Fred R	PP01.08
de la Mora Jimenez, Emmanuel	OA01.0	Gast, Kelly	PP01.16	Hochmair, Maximilian J	PP01.40
<b>E</b>		Geller, Robert	PP01.51, PP01.52	Hochmair, Maximillian J.	PP01.31
Eagle, Craig	PP01.20	Gentile, Danielle	PP01.27	Hofstetter, Wayne	PP01.06
Eaton, Cyd	PPD01.02	Gentzler, Ryan	PP01.44	Hong, Lingzhi	PP01.43
Eccles, Laura	PPD04.02	Gettinger, Scott N	PP01.40	Hooi Wong, Chew	PP01.37, PP01.38
Eisenberg, Michael	PP01.06	Giammaruco, Maristella	PP01.54	Hsia, Te-Chun	PPD02.02
Elamin, Yasir	PP01.18	Gibbs, Kim	PP01.46	Hsu, Hil	PP01.17
Elliott, Jennifer	PP01.55	Gigantone, Mark	PP01.48	Hsu, Melinda	PPD01.02
Emran, Joesph	PP01.30	Glass, Carolyn	PP01.39	Hsu, Wei-Chun	PP01.61
Esker, Stephen	PP01.47	Gogishvili, Miranda	OA01.05	Hu, Jie	PP01.11
Esteban González, E.	PP01.09	Goh, Boon Cher	PP01.74	Hu, Nan	OA01.04
Estrin, Adina	PP01.76	Gold, Kathryn A.	PP01.48	Huang, Richard	PPD02.01
Evans, Clark	PP01.79	Gómez Rueda, A.	PP01.09	Huang, Wen-Tsung	OA01.07
<b>F</b>		Gordo Flores, R.	PP01.09	Hufham, Julie	PP01.02
Fan, Pang-Dian	PP01.48	Gordon, Sean	PP01.15	Husain, Marium	PP01.25
		Gosangi, Babina	PP01.12	Hwang, Yoohwa	PP01.19

<b>I</b>					
Iadeluca, Laura	PP01.37, PP01.38	Kittrell, Natalie	PP01.10	Linardou, Helena	PP01.22
Iams, Wade T	PP01.56	Kocherginsky, Masha	PP01.13,	Lingua, Alejo	OA01.04
Insa Molla, A.	PP01.09		PP01.49, PP01.73	Liptay, Michael	PP01.33
Irigoyen Alvarez, Angel	PP01.65	Koczywas, Marianna		Lisi, Monica	PP01.63
Isla Casado, D.	PP01.09			Litovchick, Larisa	PP01.32
Itzkovich, Yahav	PP01.78	Komiya, Takefumi	PPD03.01	Liu, Dongyan	PP01.34
		Korytowsky, Beata	PP01.70, PP01.78	Liu, Stephen	PP01.67
		Kosari, Farhad	PPD04.01	Liu, Yuyin	PP01.40
		Kosmas, Epaminondas	PP01.22	Liu, Ziyue	PP01.64
<b>J</b>		Kothari, Arpit	PP01.58	Lizcano Aguilar, Nestor	PP01.65
Jain, Deepali	PP01.23, PP01.24	Koufos, Nikolaos	PP01.22	Lo Russo, Giuseppe	PP01.01
Jain, Rahul	PP01.78	Kowanetz, Marcin	PP01.11	Lofgren, Katherine T.	PP01.36
Jalal, Shadia	PP01.44	Krulewicz, Stan	PP01.37, PP01.38	Lopes, Gilberto	PP01.74
James CH Yang, James CH	PP01.40	Kuban, Joshua D	PP01.08	Lopez, Gabrielle	PP01.25
Jani, Chinmay	PP01.45	Kulyaba, Yaroslav	OA01.05	López Castro, R.	PP01.09
Janne, Pasi A.	OA01.07	Kumar, Sachin	PP01.23, PP01.24	López Muñoz, M. E.	PP01.09
Jänne, Pasi A.	PP01.48	Kumar, Sunil	PP01.23, PP01.24	Lopez-Martin, Javier	PP01.39
Janse, Sarah	PP01.16	Kunming, Sheryl	PP01.34	Lowy, Israel	OA01.05
Jassem, Jacek	OA01.04	Kuriakose, Emil	PP01.10	Lu, Shun	OA01.04, PPD02.02
Jheon, Sanghoon	PP01.19			Luo, Huibing	PP01.11
Jiang, Changchuan	PP01.71,	<b>L</b>		Lupinacci, Lorena	PPD04.02
	PPD04.03	La, Jennifer	PP01.05	Lutzker, Stuart	PP01.11
Jiang, Liyan	OA01.07	Lainakis, Georgios	PP01.22		
John, Thomas	OA01.04	Lammers, Philip	PP01.77	<b>M</b>	
Johne, Andreas	OA01.08, PPD02.02	Lampenfelf, Caleb	PP01.34	Ma, Rui	PPD02.03
Johnson, Lauren	OA01.02	Landi, Lorenza	PP01.54	MacDonald, Karen	PP01.51, PP01.52
Johnson, Melissa L.	PP01.10,	Lanyado, Alon	PP01.03	Madan, Karan	PP01.23, PP01.24
	PP01.48	Last, Matthew	PP01.37, PP01.38	Mahadevia, Parthiv	PP01.31
Johnson, Sarah	PPD04.01	Laurie, Melissa	PP01.70	Mahmud, Siraje	PP01.63
Jotte, Robert M	PP01.74	Le, Xiuning	OA01.08, PP01.43,	Maimon, Natalie	PP01.17
Juan Vidal, O. J.	PP01.09		PPD02.03	Majem, Margarita	PP01.17
Jung, Wonyoung	PP01.29	Lee, Genhee	PP01.29	Majem Tarruella, M.	PP01.09
Juraeva, Dilafruz	OA01.08	Lee, J. Jack	PP01.43	Malik, Prabhat S	PP01.23, PP01.24
		Lee, Jack	PP01.39, PP01.53	Mandal, Souvik	PP01.58
Kalmadi, Sujith	PP01.17	Lee, Jong-Seok	PPD04.02	Mandaj, Chiara	PP01.54
Kammer, Michael	PP01.35	Lee, Jung Eun	PP01.19	Mansfield, Aaron	PPD04.01
Kang, Danbee	PP01.29	Lee, K Adam	PP01.14	Marchand, Loïc	OA01.01
Kang, Jin-Hyoung	OA01.08	Lee, Ki Hyeong	PP01.40	Marino, Katy	OA01.02
Karagouga, Giannoula	PPD04.01	Lee, Se-Hoon	PP01.31	Mase, Vincent	PP01.12
Kari, Gabor	PP01.27	Leontis, Michail	PP01.22	Mayfield, William	PP01.60
Katchman, Benjamin A	PP01.08	Leung, Ann	OA01.01	Mazieres, Julien	PPD02.03
Kaul, Manika	OA01.05	Leventakos, Konstantinos	PP01.55	McCune, Alexa	PPD04.01
Kelley, Michael	PP01.05	Leventon, Daniel	PP01.08	McDonough, Alexandra	PP01.34
Kern, Ryan	PP01.26	Li, Benjamin	PP01.61	McKenzie, Andrew J.	PP01.63
Kerr, Keith	PP01.39	Li, Li	PPD04.02	McPherson, Monica	PP01.69
Khan, Ibrahim	PP01.30	Li, Mark	PP01.56	Meerbeeck, Jan Van	OA01.08
Kharouta, Michael	PP01.68	Li, Mingjia	PP01.25	Mehran, Reza	PP01.06
Kilickap, Saadettin	OA01.05	Li, Qing	PP01.11	Meinhardt, Anna-Lena	PP01.69
Kim, Ben	PP01.48	Li, Shunqiang	PP01.28	Meloni, Alison	PP01.17
Kim, Dong-Wan	PP01.40, PP01.48,	Li, Siyu	OA01.05	Menakuru, Sasmith	PP01.30
	PPD02.02	Li, Wenyan	PP01.77	Mendieta, Irasema	PP01.57
Kim, Hong Kwan	PP01.29	Li, Yuntong	OA01.05	Menezes, Juliana	OA01.04
Kim, Hye Mi	PP01.34	Liam, Chong Kin	PPD02.02	Metro, Giulio	PP01.17
Kim, Hye Ryun	PP01.40	Liang, Su-Ying	OA01.01	Miah, Abdul	PP01.25
Kim, Sang-We	PP01.48	Liao, Jiemin	PP01.15	Migas, John	PP01.77
Kim, Tae Min	PP01.31	Lim, Lee	PP01.56	Miller, Mattea	PPD01.02
Kim, Young-Chul	OA01.08	Lin, Huamao M	PP01.55	Millward, Michael	OA01.07



Min Chin, Tan	PP01.74
Minasi, Lori	PP01.67
Minuti, Gabriele	PP01.54
Mitchell, Paul	OA01.07
Mizutani, Hideaki	OA01.04
Modi, Ankit	PP01.58
Mohindra, Nisha	PP01.13, PP01.44, PP01.49, PP01.73
Mok, Tony	PP01.47
Morales Hernández, Karina	PP01.65
Morbeck, Igor	PP01.17
Morgensztern, Daniel	PP01.28
Mortarini, Roberta	PP01.01
Moudgalya, Hita	PP01.33
Mowlavi, Layla	PP01.15
Muesse, Jason	OA01.02
Mukkavilli, Sai Vinayak	PP01.59
Muldoon, Allison	PP01.08
Murakami, Haruyasu	PP01.48
Murphy, Stephen	PPD04.01
Musib, Luna	PP01.11
N	
Nair, Viswam	PP01.35
Najar Rodríguez, Miriam	PP01.65
Naren, Sai	PP01.59
Naveh, Navit	PP01.76, PP01.77
Neal, Joel	OA01.01
Nechaeva, Marina	OA01.05
Nerstad, amanda	PP01.79
Ng, Carmen	PP01.36
Nguyen, Ha	PP01.20
Nguyen, Trung	PP01.80
Nian, Weiqi	OA01.07
Nishio, Makoto	PP01.47, PP01.48, PPD04.02
Novello, Silvia	PP01.17
O	
O'Byrne, Kenneth John	PPD04.02
Obiozor, Cynthia	PP01.17
O'Brate, Aurora	PPD02.03
Oduah, Eziafa	PP01.32
Ogale, Sarika	PP01.36
OHara, Richard	PPD02.02
Okoye, Emmanuel	OA01.05
Olson, Sarah	PPD01.02
Orciuolo, Corrado	PP01.54
Orsini Jr., James	PP01.74
Otterson, Gregory	PP01.25
Otto, Gordon	OA01.08, PPD02.03
Owen, Dwight H	PP01.25
Oxnard, Geoffrey	PPD02.01
Oxnard, Geoffrey R.	PP01.36, PP01.45
Ö	
Özgüroğlu, Mustafa	OA01.05

P	
Padda, Sukhmani	PP01.78
Pagano, Paul C	PP01.08
Paik, Paul	PP01.10, PPD02.03
Paik, Paul K	OA01.08
Panaccione, Alexander	PP01.31
Park, Junhee	PP01.29
Patel, Bindiya G.	PP01.28
Patel, Jyoti	PP01.13, PP01.44, PP01.49, PP01.73
Patel, Mehul	PP01.77
Patel, Mohini	PP01.45
Paulson, Steven	PP01.63
Pavón-Romero, Lenin	PP01.57
Paz-Ares, Luis G.	OA01.04, OA01.08, PPD04.02
Peikert, Tobias	PPD04.01
Pelizzari, Giacomo	PP01.17
Peña Campos, Celene	PP01.65
Pepin, Kym	PP01.28
Peralta Muñoz, S.	PP01.09
Pérez-Sánchez, Gilberto	PP01.57
Perimbeti, Stuthi	PP01.71, PPD04.03
Petty, William	PP01.17
Phan, Donna	PP01.04
Phelps, Mitch	PP01.25
Pilcher, Carly	PP01.25
Pitcher, Trevor	PP01.35
Plank, April	PP01.07
Podder, Tarun	PP01.21
Poleri, Claudia	PP01.39
Ponce Aix, Santiago	PP01.09
Popat, Sanjay	PP01.40
Posadas, Juan	PP01.39
Posadas Ruiz, Juan	PP01.53
Pouliot, Jean-Francois	OA01.05
Prakash, Ram	PP01.58
Prelaj, Arsela	PP01.01
Presley, Carolyn	PP01.16
Presley, Carolyn J	PP01.25
Price, Richard	PP01.36
Prince, Patricia	PP01.76
Proto, Claudia	PP01.01
Protsenko, Svetlana	OA01.04
Putha, Preetham	PP01.58, PP01.59
Q	
Qi, Zhenhao	PP01.48
Que, Do Kim	PP01.80
Quintero, Jorge Rodriguez	PP01.04
R	
Radwan, Amr	PP01.45
Ragam, Avanthi	PP01.13, PP01.49, PP01.73
Rajaram, Ravi	PP01.06
Ramalingam, Suresh S.	PPD04.02

Raskin, Jo	PPD02.03
Raskina, Kira	PPD02.01
Raymond, Victoria	PP01.20
Reagan, Lisa	PP01.07
Reck, Martin	OA01.04, PP01.47, PPD04.02
Reckamp, Karen	PP01.44
Reddy, Bhargava	PP01.59
Reddy, Bharghava	PP01.58
Reed, Rebecca	PP01.08
Reid, Michal	PP01.26
Reinmuth, Niels	OA01.04
Reisenauer, Janani	PP01.26
Reiter, Michael	PP01.07
Remolina Bonilla, Yuly	PP01.65
Rengarajan, Badri	PP01.76
Resuli, Blerina	PP01.54
Reyes, Felipe	OA01.04
Riccardi, Rachel	PP01.04
Rice, David	PP01.06
Riess, Jonathan W.	PP01.10
Rietschel, Petra	OA01.05
Roden, Anja	PP01.39
Rodriguez, Estelamari	PP01.15
Rohatgi, Anjali	PP01.28
Rolfo, Christian	PP01.15
Rongo, Ava	PP01.07
Rose, Jennifer B.	PP01.31
Ross, Ryan	PP01.61
Roth, Jack	PP01.06
Rubio Anguiano, Brenda Lorena	PP01.65
Ruffin, Ayana	PP01.34
S	
Sabari, Joshua	PP01.31
Saikia, Jyoutishman	PP01.23, PP01.24
Sakai, Hiroshi	PPD02.03
Salih, Ahmed	PP01.30
Samantas, Epaminondas	PP01.22
Samol, Jens	PP01.74
Sánchez Hernández, Juan Jose	PP01.65
Sánchez Roman, Eduardo	PP01.65
Sanchez-Espiridion, Beatriz	PP01.39, PP01.53
Sands, Jacob	PP01.50, PPD02.01
Sangha, Randeep	PPD04.02
Saqui, Anjali	PP01.39
Sathyamurthy, Saigopal	PP01.58, PP01.59
Schaefer Klein, Janet	PPD04.01
Schell, Scott	PP01.79
Schenker, Michael	OA01.05
Scheusan, Roxana-Ioana	OA01.05
Schioppa, Claudio A.	PP01.31

Schreeder, Daniel	PP01.77
Schrock, Alexa	PPD02.01
Schweitzer, Catherine	PP01.25
Scilla, Katherine	PP01.74
Scipione, Fatima	PP01.46
Scofield, Amanda	PP01.70
Secor, Austin	PP01.25
Seder, Christopher	PP01.33
Seebach, Frank	OA01.05
Seetharamu, Nagashree	PP01.32
Sepesi, Boris	PP01.06, PP01.18
Sezer, Ahmet	OA01.05
Shaffer, Tristan	PP01.56
Shafquat, Afrah	PP01.78
Shafrin, Jason	PP01.70
Shah, Anuj	PP01.36
Shah, Palmi	PP01.33
Shahani, Shobha	PP01.64
Sharma, Neha	PP01.21
Sharma, Sadhna	PP01.62
Shields, Peter	PP01.25
Shih, Jin-Yuan	PP01.31
Shim, Young Mog	PP01.29
Shin, Dong Wook	PP01.29
Shin, Sang Won	PPD02.02
Sholl, Lynette	PP01.39
Silas, Lindsay	PP01.14
Silberman, Philip	PP01.13, PP01.49, PP01.73
Singh, Aditi P.	PP01.50
Skoulidis, Ferdinandos	PP01.10
Slater, Dennis	PP01.77
Smadbeck, James	PPD04.01
Smit, Egbert F.	PP01.48, PPD02.03
Sohail, Syeda Sarosh	PP01.04
Somasundaram, Ashwin	PP01.34
Sonpavde, Guru	PP01.50
Soo, Ross Andrew	PPD02.02
Sorrentino, Rosalinda	PP01.54
Spakowicz, Daniel	PP01.25
Spigel, David	PP01.50
Spira, Alexander	PP01.31
Spira, Alexander I	PP01.40
Srinivas, Sandy	PP01.50
Srivastava, Shreya	PP01.59
Stabile, Laura	PP01.34
Steliga, Matthew	OA01.02
Sternberg, David	PP01.47, PP01.48
Steuer, Conor E.	PP01.48
Stevenson, James	PP01.17
Stiles, Brendon	PP01.04
Stroh, Christopher	OA01.08
Sturgis, Charles D.	PP01.26
Su, Chloe	OA01.01, PP01.05
Su, Roger	PP01.60
Su, Wu-Chou	OA01.07, PP01.48
Subbiah, Vivek	PP01.50

Subramanian, Hari	PP01.26
Sumrow, Brad	PP01.10
Sun, Zequn	PP01.13, PP01.49, PP01.73
Swisher, Stephen	PP01.06, PP01.18
T	
Tadepalli, Manoj	PP01.59
Tahvilian, Shahram	PP01.08
Takamori, Shinkichi	PPD03.01
Talwai, Aniketh	PP01.78
Tan, Min-Han	PP01.74
Tan, Yew Oo	PP01.74
Tanoue, Lynn	PP01.12
Tapan, Umit	PP01.45, PPD02.01
Thomaidou, Despina	PP01.37, PP01.38
Thomas, Michael	PP01.40, PPD02.03
Tiseo, Marcello	PP01.40
Toh, Chee Keong	PP01.74
Torri, Valter	PP01.01
Toschi, Luca	PP01.17
Traube, Leah	PP01.12
Travis, William	PP01.39
Trejo, Michael	PP01.08
Trejo Rosales, Raúl Rogelio	PP01.65
Tukachinsky, Hanna	PPD02.01
Turner, Michelle	PPD01.02
U	
Udell, Julia	PPD04.01
Urban, Lazlo	PPD04.02
Uribe, Dubeth	PP01.25
V	
Vakkalagadda, Chetan	PP01.13, PP01.73
Vakkalagadda, Chetan V.	PP01.49
Vanapalli, Prakash	PP01.58
Vaporciyan, Ara	PP01.06, PP01.18
Varrieur, Tracy	PP01.17
Vasmatzis, George	PPD04.01
Vassias, Antonios	PP01.22
Veillon, Remi	PPD02.03
Vélez Martínez, Amairany	PP01.65
Vento-Gaudens, Erika	PP01.20
Verini, Christine	PP01.46
Vicente Baz, D.	PP01.09
Vieira, Maria Cecilia	PP01.61
Villaruz, Liza C.	PP01.50
Vincente Baz, David	OA01.08
Viteri, Santiago	OA01.08, PPD02.03
Vlahiotis, Anna	PP01.61
Vo, Luan	PP01.59
W	
Wakelee, Heather	OA01.01
Walden, Paul	PP01.51, PP01.52

Walker, Angela	PP01.39, PP01.53
Walsh, Garrett	PP01.06
Wan, Yin	PP01.55
Wang, Mengzhao	OA01.07
Wang, Xue	PP01.76
Waqar, Saiama	PP01.28
Ward, Jeffrey P.	PP01.28
Warrier, Prashant	PP01.59
Wei, Lai	PP01.25
Weipert, Caroline	PP01.15
Weissferdt, Annika	PP01.39
Westlake, Bill	PP01.79
Wijeratne, Shani	PP01.39, PP01.53
Williams, Meredith	PP01.72
Wilner, Keith D.	PP01.61
Wiltshire, Robin	PP01.37, PP01.38
Wistuba, Ignacio	PP01.39, PP01.53
Woodard, Gavitt	PP01.12
Wu, Elaine	PP01.47
Wu, Elaine Y.	PP01.48
Wu, Julie	OA01.01, PP01.05
Wu, Yi-Long	PP01.47, PPD02.02, PPD02.03
Wynes, Murry	PP01.39, PP01.53
X	
Xia, Caihong	PP01.17
Y	
Yang, James Chih-Hsin	OA01.07, PPD02.02, PPD02.03
Yang, Tsung-Ying	OA01.07
Yankelevitz, David F	PP01.08
Yin, Jun	PPD04.01
Yin, Yu	PP01.55
Yip, Rowena	PP01.08
Young, Matt	PP01.55
Yu, Helena	PP01.47
Yu, Stephen	PP01.72
Yun, Karen	PP01.66
Z	
Zarroca Palacio, Santiago	PP01.65
Zer, Alona	PP01.17
Zhang, Pingkuan	PP01.40
Zhang, Xiaoqing	OA01.04
Zhang, Yiping	PPD02.02
Zhao, Jun	PPD02.02, PPD02.03
Zhao, Songzhu	PP01.25
Zhao, Yanqiu	OA01.07
Zheng, Li	OA01.07
Zhong, Fengming	PP01.69
Zhou, Jianying	OA01.07, PPD02.02
Zhu, Helen	PP01.53
Zhu, Hui	PP01.39
Zhu, Jeffrey	PP01.08
Zhu, Viola W.	OA01.07
Zyuhai, Kasimova	OA01.05



# EXHIBIT & INDUSTRY SUPPORTER INFORMATION



#NACLC22

#NACLC22 | [nalc2022.iaslc.org](https://nalc2022.iaslc.org)

## Exhibit & Industry Supporter Information

📍 Exhibit and Poster Hall | Chicago Ballroom FGH | 5th Floor

### Exhibit Hours

Saturday, September 24	09:30 - 18:00
Sunday, September 25	09:15 - 12:30

## Exhibition Events & Highlights

### NETWORKING BREAKS

On Saturday, September 24 and Sunday, September 25, refreshments are available for registered delegates in the Chicago Ballroom FGH on the 5th Floor during the morning and afternoon Networking Breaks.

Saturday, September 24	09:30 - 10:00 14:30 - 15:00
Sunday, September 25	09:15 - 09:45

### POSTER SESSIONS

The Poster Sessions are an important educational part of this Conference. All poster presentations are located in the Exhibit and Poster Hall. All poster presentations have been assigned a consecutive publication number for locating the abstract / poster in this Program Book and the Abstract Book which corresponds to the Poster Board Numbers.

For further details regarding Poster display and author stand by times, please refer to page 21 in this Program Book.





Industry Supporter & Exhibitor List

DIAMOND

REGENERON®

PLATINUM

abbvie

Genentech  
A Member of the Roche Group


GOLD







Exhibit Floor Plan



Booth #	Company
1	IASLC
2	Regeneron
3	AbbVie
4	Merck
5	Blueprint Medicines
6	Tempus
7	Genentech #1
9	Guardant Health
10	Eli Lilly and Company
11	Genomic Testing Cooperative
12	Takeda
13	Novocure Inc.
14	EMD Serono
15	Amgen Inc.
16	Jazz Pharmaceuticals
17	Janssen Pharmaceuticals
18	Genentech #2



## Exhibitor Descriptions

### Booth 3



AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of

tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at [www.abbvie.com](http://www.abbvie.com).

### Booth 15



Amgen is a worldwide leader in biotechnology. For more than forty

years, we've pursued some of the greatest challenges facing human health, marrying science and technological innovation with the passion of our staff, to serve patients and find new solutions that meet the growing demand for better quality healthcare for more people worldwide.

### Booth 5



Blueprint Medicines is a global precision therapy company that aims to invent medicines for people with cancer and blood disorders.

### Booth 10



Lilly unites caring with discovery to create medicines that make life better for people around the world.

### Booth 14



At EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany, in the US and Canada, our scientific

approach in oncology focuses on oncogenic pathways, immuno-oncology, and DNA damage response. To deliver breakthrough cancer therapies, we complement our internal expertise and development programs with scientific collaborations to improve trial designs, accelerate treatment development, and partner on exciting asset programs and integrated innovations. We aim to deliver personalized treatment options that may potentially transform cancer care.

### Booth 7 & 18



For more than 40 years, we've been following the science, seeking solutions to unmet medical needs.

As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions. We are headquartered in South San Francisco, California.

### Booth 11



Genomic Testing Cooperative (GTC) is a different kind of cancer diagnostic laboratory. Our cooperative model allows us to

partner with laboratories, hospitals, oncology practices, and medical professionals to share resources which create efficiencies in cost, turnaround time, and quality. Customers can benefit from either of our two business models which best suits their needs. The first is a traditional reference lab model in which GTC can white label our report and allow the co-op member to build their NGS business with their own branding. The second model helps labs internalize and turn their NGS oncology send-out volume into a revenue-generating opportunity with GTC's technology. In creating a network of co-op partners, we help results get to physicians faster, share knowledge more easily, and generate better outcomes for patients.

## Exhibitor Descriptions

### Booth 9



Guardant Health is a leading precision oncology company focused on helping

conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening.

### Booth 1



The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership

includes more than 6,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the *Journal of Thoracic Oncology*, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit [www.iaslc.org](http://www.iaslc.org) for more information.

### Booth 17



At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical

Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at [www.janssen.com](http://www.janssen.com).

Follow us at [www.twitter.com/JanssenGlobal](https://twitter.com/JanssenGlobal).

### Booth 16



Jazz Pharmaceuticals plc (Nasdaq:JAZZ) is a global biopharma-

ceutical company dedicated to developing medicines for people with serious diseases — often with limited or no options.

### Booth 4



At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to

bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.




Exhibitor Descriptions

Booth 13



Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. Headquartered in Rosh HaAyin, Israel, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit [Novocure.com](http://Novocure.com) and follow @Novocure on LinkedIn and Twitter.

Booth 2



Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.


Booth 12



At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We ensure a tight connection from research to development to commercialization and rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to patients. Our demonstrated leadership in the treatment of hematologic cancers and solid tumors combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide.

For more information, visit [www.takedaoncology.com](http://www.takedaoncology.com).

Booth 6



Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

Visit the IASLC Membership Booth Today!

JOIN US!

New Members Can Join During the ELCC 2022 for a DISCOUNTED RATE!

IASLC  
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER  
Conquering Thoracic Cancers Worldwide





# INDUSTRY SPONSORED SYMPOSIA & SATELLITE CME SYMPOSIA



## Industry Sponsored Symposia & Satellite CME Symposia Saturday, September 24, 2022

**IS01 - Satellite CME Symposium by PeerView:** Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions



Chicago Ballroom E | 5th Floor

06:45 - 07:45 IS01.01: Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions  
*Tao Feek Owonikoko, United States, Carl M. Gay, United States & Jacob Sands, United States*

**IS02 - Industry Sponsored Symposium by Regeneron:** An FDA Approved Treatment Option in Advanced NSCLC



Chicago Ballroom ABCD | 5th Floor

12:00 - 13:00 IS02.01 Discussion of a New Treatment Option for Patients with Advanced SCLC  
*Eric Nadler, United States*

**IS03 - Industry Sponsored Symposium by Merck:** Personalizing Your Approach With First-Line Treatment Options for mNSCLC

Chicago Ballroom E | 5th Floor

12:00 - 13:00 IS03.01: Personalizing Your Approach With First-Line Treatment Options for mNSCLC  
*Marsha Jones, United States & Kelly Pendergrass, United States*

**IS04 - Satellite CME Symposium by PeerView:** Are You Prepared for the New Wave of ADCs in NSCLC? Innovative Approaches and Practical Considerations in Targeting HER2, HER3, TROP2, and Other Alterations in Advanced Lung Cancer



Chicago Ballroom ABCD | 5th Floor

19:30 - 20:30 IS04.01: Are You Prepared for the New Wave of ADCs in NSCLC? Innovative Approaches and Practical Considerations in Targeting HER2, HER3, TROP2, and Other Alterations Advanced Lung Cancer  
*Marina Chiara Garassino, United States, Hossein Borghaei, United States & Stephen V. Liu, United States*

## Sunday, September 25, 2022

**IS05 - Satellite CME Symposium by PeerView:** Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR Mutations



Chicago Ballroom E | 5th Floor

06:45 - 07:45 IS05.01: Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR Mutations  
*Natasha Leighl, Canada, Zofia Piotrowska, United States & Catherine Shu, United States*

**IS06 - Industry Sponsored Symposium by Janssen:** NSCLC With EGFR Exon 20 Insertion Mutations: A Clinical Review and Practical Considerations



Chicago Ballroom E | 5th Floor

12:30 - 13:30 IS06.01: NSCLC With EGFR Exon 20 Insertion Mutations: A Clinical Review and Practical Considerations  
*David Waterhouse, United States*



# LUNG CANCER CONSIDERED



*with Dr. Stephen Liu and Dr. Narjust Florez*

**The official podcast of the IASLC.**

Tune in each month for conversations with the researchers, healthcare professionals, patients and advocates from around the world who are making a difference in the treatment of thoracic cancers.

→ Find new podcast episodes at  
**IASLC.org/Lung-Cancer-Considered**

Simply scan the QR Code below and start listening today.



Lung Cancer Considered  
is funded in part by:  
AstraZeneca,  
Bristol Myers Squibb,  
Lilly Oncology, and  
Merck KGaA.



## JTO CLINICAL AND RESEARCH

*The official open access journal of the IASLC*

Editor-in-Chief:

**Alex A. Adjei, MD, PhD, FACP**

*Chairman, Taussig Cancer Institute – Cleveland Clinic, Cleveland, OH USA*

**JTO Clinical and Research Reports** is the official open access journal of the International Association for the Study of Lung Cancer. It complements the *Journal of Thoracic Oncology* by offering authors a gold open access publication option and publishing the following article types in particular:

- Phase I trials
- Well performed single-arm phase II trials
- Subset analyses of published trials
- Impactful retrospective studies
- Database and registry analysis
- Large institutional series
- High-quality case reports
- Region-specific clinical trials
- Subspecialty specific thoracic oncology studies
- Selected high-quality meeting reports




INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER

Now  
indexed in  
PubMed  
Central


## JTO CLINICAL AND RESEARCH REPORTS



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER



visit  
**jtocrr.org**



Learn more at **JTOCRR.org**





# IASLC 2022-23

## MEETINGS SCHEDULE

### IASLC 2022 Asia Conference on Lung Cancer

October 27-29, 2022  
Nara, Japan  
#ACLC22

### IASLC 2023 Latin America Conference on Lung Cancer

January 25-27, 2023  
Montevideo, Uruguay  
#LALCA23

### IASLC 2023 Targeted Therapies of Lung Cancer Meeting

February 22-25, 2023  
Santa Monica, California  
#TTLC23

### IASLC 2023 World Conference on Lung Cancer

September 9-12, 2023  
Singapore  
#WCLC23



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER  
Conquering Thoracic Cancers Worldwide

[IASLC.org/Meetings-Webinars](https://iaslc.org/Meetings-Webinars)

Scan the  
QR code for  
information  
on upcoming  
meetings and  
webinars.



\* Location and dates subject to change

### CONNECT WITH US

 @IASLC

 facebook.com/IASLC

 @iaslungcancer

 linkedin.com/IASLC

 IASLC

